Poster Presentations Session I
Poster Presentations Session I Monday, 6 November 2017
POSTERS SET-UP: 8:30 - 8:45
POSTERS DISPLAY HOURS: 8:45 - 13:45
POSTER AUTHOR DISCUSSION: 12:45 - 13:45
POSTERS DISMANTLE: 13:45


Poster display locations are shown below the poster codes
CANCER - Clinical Outcomes Studies
PCN1
A1
LOWER ANTERIOR RESECTION SURGICAL COMPLICATIONS IN COLORECTAL CANCER PATIENTS: ASSOCIATION WITH LENGTH OF STAY, DISCHARGE TO INSTITUTIONAL CARE, AND 90-DAY READMISSION
Ammann EM1, Goldstein LJ2, Johnston SS1
1Johnson & Johnson Co., New Brunswick, NJ, USA, 2Johnson & Johnson, Markham, ON, Canada

PCN2
A2
DETRIMENTAL IMPACT OF TOXICITY ON QUALITY OF LIFE IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIBOR SORAFENIB
Hudgens S1, Misurski D2, Meier G2
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA

PCN3
A3
PATTERN OF CHEMOTHERAPY RELATED ADVERSE EFFECTS AMONG ADULT CANCER PATIENTS TREATED AT GONDAR UNIVERSITY REFERRAL HOSPITAL, ETHIOPIA: A CROSS SECTIONAL STUDY
Belachew sA, Erku dA, Mekuria Ab, Gebresilassie BM
University of Gondar, Gondar, Ethiopia

PCN4
A4
ASSESSMENT OF PATIENTS ADMITTED FOR DRUG-RELATED PROBLEMS IN CANCER CHEMOTHERAPY
Reji RS1, Kumar B2, Nair S2, Thunga G3, Udupa KS4
1Manipal University, Manipal, India, 2Dept. of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka State., India, 3Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 4KMC, Manipal, manipal, India

PCN5
A5
COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 400 MG CAPSULES BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED NON-GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)
Sackeyfio A1, Gill J2, Hettle R3, Siddiqui K2, Friedlander M4, Ledermann JA5
1AstraZeneca, Cambridge, UK, 2PAREXEL International, Chandigarh, India, 3PAREXEL International, London, UK, 4University of New South Wales Clinical School, New South Wales, Australia, 5University College London, London, UK

PCN6
A6
COMPARATIVE EFFICACY AND SAFETY OF OLAPARIB 300 MG TABLETS BID AND NIRAPARIB 300 MG TABLETS QD AS MAINTENANCE TREATMENT AFTER RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED GERMLINE BRCA-MUTATED OVARIAN CANCER (PSROC)
Hettle R1, Sackeyfio A2, Gill J3, Siddiqui K3, Nussey F4, Friedlander M5
1PAREXEL International, London, UK, 2AstraZeneca, Cambridge, UK, 3PAREXEL International, Chandigarh, India, 4Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK, 5University of New South Wales Clinical School, New South Wales, Australia

PCN7
A7
COMPARATIVE EFFICACY AND SAFETY OF INTERVENTIONS FOR PREVENTING CHEMOTHERAPY INDUCED ORAL MUCOSITIS IN ADULT CANCER PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Kengkla K, Kaewpanan T, Kaewthong J, Ruankon S, Subthaweesin C, Saokaew S
University of Phayao, Muang, Phayao, Thailand

PCN8
A8
COMPARATIVE EFFECTIVENESS OF NOVEL TREATMENTS FOR ADVANCED MELANOMA: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF EFFECTIVENESS AND SAFETY OUTCOMES
Franken M1, Leeneman B2, Gheorghe M1, Buyukkaramikli N1, Gerrits J2, van der Helm I2, Uyl-De Groot C1, Versteegh M1, Haanen J3, van Baal P2
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 3Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

PCN9
A9
WITHDRAWN

PCN10
A10
EPIDEMIOLOGY OF BRAFV600-MUTATED METASTATIC MELANOMA IN EUROPE: A SYSTEMATIC REVIEW
Rahhali N1, Chalem Y1, Arkoub H2, Chollet J1, Bobrowska A3, Drane E3, Uchea C3, Wulund L3, Leonard S3
1Pierre Fabre SA, Boulogne-Billancourt, France, 2Pierre Fabre Medicament, Boulogne-Billancourt France, France, 3Costello Medical Consulting Ltd, Cambridge, UK

PCN11
A11
PATIENT CHARACTERISTICS, SKELETAL RELATED EVENTS (SRE) AND RENAL IMPAIRMENT (RI) IN PATIENTS WITH MULTIPLE MYELOMA (MM): A PATIENT CHART AUDIT IN EU5
Mateos M1, Cavo M2, Fink L3, Koneswaran N3, Giannopoulou C4, Niepel D5, Gonzalez-McQuire S5, Intorcia M4
1University Hospital of Salamanca, Salamanca, Spain, 2Bologna University School of Medicine, Bologna, Italy, 3Kantar Health, Paris, France, 4Amgen GmbH, Zug, Switzerland, 5Amgen (Europe) GmbH, Zug, Switzerland

PCN12
A12
IMPACT OF DIFFERENT BASELINE DEFINITIONS ON THE INCIDENCE OF RELEVANT OUTCOMES ASSOCIATED WITH CANCER FOLLOWING AN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) DIAGNOSIS
Linden S1, Banos Hernaez AM2, Redig J2, Nilsson J2, Justo N2
1Boehringer Ingelheim, Ingelheim am Rhein, Germany, 2Mapi Group, Stockholm, Sweden

PCN13
A13
ASSOCIATION BETWEEN SOCIOECONOMIC DEPRIVATION AND CANCER INCIDENCE AND OUTCOMES AMONG ENGLISH CCGS
Davies J, Gray P, Hickey DA
OPEN Access Consulting (an OPEN Health Company), London, UK

PCN14
A14
NETWORK META-ANALYSIS OF TREATMENTS FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
Tremblay G1, Meier G2, Copher R2, Misurski D2, Pan J2, Baig M2, Tamai T2, Kraljevic S3, Shor A1, Forsythe A1
1Purple Squirrel Economics, New York, NY, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Eisai Co., Ltd., Hatfield, UK

PCN15
A15
SECOND-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER: A SYSTEMATIC LITERATURE REVIEW
Bharmal M1, Guenther S1, Rosen G2, Kearney M1, Phatak H2, Kempel-Waibel A1
1Merck KGaA, Darmstadt, Germany, 2EMD Serono, Billerica, MA, USA

PCN16
A16
COMPARATIVE STUDY OF HEALTHCARE RESOURCE UTILIZATION (HRU) OUTCOMES BETWEEN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH IBRUTINIB VERSUS NON-IBRUTINIB TREATED PATIENTS
Nero D1, Chung J1, Kish J2, Nabhan C2
1Cardinal Health Specialty Solutions, Dallas, TX, USA, 2Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN17
A17
NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENT PROFILES; FINDINGS FROM AN OBSERVATIONAL CHART REVIEW IN FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM
Mateos M1, Raab MS2, Cavo M3, Gonzalez-McQuire S4, Fink L5, Schoen P4, Biedermann P4
1University Hospital of Salamanca, Salamanca, Spain, 2Heidelberg University Hospital, Heidelberg, Germany, 3Bologna University School of Medicine, Bologna, Italy, 4Amgen (Europe) GmbH, Zug, Switzerland, 5Kantar Health, Paris, France

PCN18
A18
MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF CRIZOTINIB WITH STANDARD OF CARE IN PROGRESSED NSCLC ALK+ PATIENTS BASED ON REAL-WORLD EVIDENCE (RWE) AND CLINICAL TRIAL DATA IN THE CZECH REPUBLIC
Pasztor B1, Losenicky L2, Mazan P2, Duba J1, Kolek M1
1OAKS Consulting s.r.o., Prague 9, Czech Republic, 2Pfizer PFE, spol. s r.o., Prague 5, Czech Republic

PCN19
A19
ESTIMATION OF THE HEALTH BENEFIT ASSOCIATED WITH A POTENTIAL DENOSUMAB-INDUCED EXTENSION OF PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS
Sabatelli L, Jamotte A, Giannopoulou C, Intorcia M
Amgen GmbH, Zug, Switzerland

PCN20
A20
MERKEL CELL CANCER: POOR RESPONSE TO CHEMOTHERAPY EXPOSES SIGNIFICANT UNMET NEED
Klink AJ1, Phatak H2, Bharmal M3, Kaufman J1, Feinberg B4
1Cardinal Health, Dublin, OH, USA, 2EMD Serono, Billerica, MA, USA, 3EMD Serono, Rockland, MA, USA, 4Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN21
A21
SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
Forsythe A1, Arondekar B2, Tremblay G1, Chan G2, Su Y3
1Purple Squirrel Economics, New York, NY, USA, 2Pfizer Inc, Collegeville, PA, USA, 3Pfizer Inc, New York, NY, USA

PCN22
A22
ANALYSIS OF RECENT APPROVALS OF IMMUNO-ONCOLOGY DRUGS ACROSS ENGLAND, SCOTLAND, GERMANY AND FRANCE
Ziomek J1, El Mouaddin N2, Ng T1, Ovcinnikova O1, Taveau C3
1Mapi, London, UK, 2Mapi Group, Nanterre, France, 3Mapi, Nanterre, France

PCN23
A23
EVALUATION OF THE CLINICAL EFFECTIVENESS OF AXITINIB, CABOZANTINIB, EVEROLIMUS, NIVOLUMAB, SUNITINIB AND BEST SUPPORTIVE CARE (BSC) IN PREVIOUSLY TREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA (AMRCC): A SYSTEMATIC REVIEW AND MIXED-TREATMENT COMPARISION (MTC)
Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, Masento N, Salih F
BMJ, London, UK

PCN24
A24
COMPARING ITC RESULTS FROM LENVATINIB PLUS EVEROLIMUS FOR SECOND-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA: CROSSOVER VERSUS NO CROSSOVER
Tremblay G1, Garib SA1, Meir G2, McElroy HJ3, Guo M2
1Purple Squirrel Economics, New York, NY, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA, 3Covance (Asia) Pte Ltd., Singapore, Singapore

PCN25
A25
CLINICAL TRIAL SIMULATIONS BASED ON A META-ANALYSIS OF STUDIES IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC ADENOCARCINOMA PANCREATIC CANCER RECEIVING GEMCITABINE (GEM) ALONE OR IN COMBINATION
Bennetts M1, Nickens DJ2, Thurm HC2, Hernandez CJ2, Ahadieh S3, Amantea MA2
1Pfizer Limited, Sandwich, UK, 2Pfizer Inc, San Diego, CA, USA, 3Pfizer Inc, Groton, CT, USA

PCN26
A26
EVALUATING THE CLINICAL EFFECTIVENESS OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS ALL OTHER TREATMENTS FOR PREVIOUSLY TREATED, UNRESECTABLE, HER2-POSITIVE METASTATIC BREAST CANCER (MBC): A MIXED TREATMENT COMPARISON (MTC)
Paracha N, Irahara N, Schuhmacher C
F. Hoffmann-La Roche Ltd, Basel, Switzerland

PCN27
A27
TIME TO CLINICALLY MEANINGFUL WORSENING IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB OR SORAFENIB
Hudgens S1, Misurski D2, Meier G2
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA

PCN28
B1
SYSTEMATIC LITERATURE REVIEW FOR TREATMENT OUTCOMES (INCLUDING IMMUNO-ONCOLOGY TREATMENT) AMONG PATIENTS WITH STAGE 3 UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
Zhou Z1, Song J2, Ouwens MJ3, Huhn M3, Jiang H4, Zhang Y5, Dalevi D3
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., Los Angeles, CA, USA, 3Astrazeneca, Molndal, Sweden, 4Astrazeneca, Gaithersburg, MD, USA, 5AstraZeneca, Gaithersburg, MD, USA

PCN29
B2
WITHDRAWN

PCN30
B3
CLINICAL COMPARISON OF FIRST-LINE PLATIN CHEMOTHERAPY REGIMENS IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) USING GERMAN REGISTRY DATA
Haas JS1, Meise D1, Ogbonnaya A2, Braun S1, Eaddy M3, Daeßler K4, Sandner R5, Binninger A6, Jaenicke M6, Chiabudini M6, Marschner N7
1Xcenda GmbH, Hannover, Germany, 2Xcenda, LLC, Scientific Consulting, Palm Harbor, FL, USA, 3Xcenda LLC, Palm Harbor, FL, USA, 4Onkologische Schwerpunktpraxis, Freital, Germany, 5Gemeinschaftspraxis Dr. Prenninger & Dr. Sandner, Passau/Kohlbruck am Messepark, Germany, 6iOMEDICO AG, Freiburg, Germany, 7Praxis für Interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany

PCN31
B4
OCCURRENCE OF SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH SOLID TUMORS (ST) AND MULTIPLE MYELOMA (MM) IN GERMANY: EARLY VERSUS LATE INITIATION OF SRE PREVENTATIVE AGENTS (SPA)
Intorcia M1, Hohmann D2, Giannopoulou C1, Ansorge S3
1Amgen GmbH, Zug, Switzerland, 2Amgen GmbH, Munich, Germany, 3arvato health analytics, Munich, Germany

PCN32
B5
USE OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN ROUTINE CLINICAL PRACTICE
Vallez-Valero L, Rius-Perera J, Gilabert Sotoca M, Mangues-Bafalluy I, Schoenenberger JA, Salud-Salvia MA
Hospital Universitari Arnau de Vilanova, Lleida, Spain

PCN33
B6
TREATMENT STRATEGIES AND OUTCOMES IN PATIENTS TREATED FOR RELAPSED REFRACTORY MULTIPLE MYELOMA OVER 3 YEARS: PREMIERE STUDY
Méndez I1, Zagorska A2, Artime E1, Lefevre C2, San José B1, González García P3, Martin-Regueira P3, Qizilbash N1
1OXON Epidemiology, Madrid, Spain, 2Bristol-Myers Squibb, Paris, France, 3Bristol-Myers Squibb, Madrid, Spain

PCN34
B7
COMPARING SURGICAL THERAPY AND HORMONAL THERAPY IN INCIDENCE OF CARDIOVASCULAR DISEASE AMONG PROSTATE CANCER PATIENTS IN KOREA
Kang M, Park E, Shim J, Choi I, Park J, Kang S, Yang J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea, Republic of (South)

PCN35
B8
NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) AS A PREDICTOR FOR RECURRENCEIN PATIENTS WITH STAGE III MELANOMA
Ma J1, Kuzman J2, Ray A3, Khong B4, Lawson BO5, Xuan S6, Khong HT7
1University of Utah, Salt Lake City, UT, USA, 2Sanford USD Medical Center, Sioux Falls, SD, USA, 3Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA, 4White Memorial Medical Center, Los Angeles, CA, USA, 5HonorHealth Scottsdale Shea Medical Center, Scottsdale, AZ, USA, 6University of Southern California, Los Angeles, CA, USA, 7Moffitt Cancer Center, Tampa, FL, USA

PCN36
B9
EXPLORING THE EFFICACY AND SAFETY OF RADIOFREQUENCY ABLATION IN PATIENTS WITH SPINAL METASTASES: A SYSTEMATIC REVIEW
Brasseur P1, Gurung B2, Halfpenny NJ2, Eaton J2
1Medtronic plc, Tolochenaz, Switzerland, 2ICON Health Economics and Epidemiology, Abingdon, UK

PCN37
B10
SAFETY AND EFFICACY OF OSIMERTINIB AS A THERAPY IN PATIENTS WITH EGFR T790M POSITIVE NON SMALL CELL LUNG CANCER PATIENTS: A SYSTEMATIC REVIEW
Gadi HR, Ganta mR, Voleti VB, Rayavarapu jE, Thatavarti R
Excelra Knowledge Solutions, Hyderabad, India

PCN38
B11
TRASTUZUMAB AS A THERAPY VERSUS OTHER TREATMENT REGIMENS IN PATIENTS WITH HER2 POSITIVE BREAST CANCER: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
Yerram Sk, Gadi HR, Kethireddy K, Thatavarti R
Excelra Knowledge Solutions, Hyderabad, India

PCN39
B12
INTENSITY MODULATED RADIATION THERAPY IN MALIGNANT PLEURAL MESOTHELIOMA; A PIOLT FOR TREATMENT OUTCOMES AND COST-EFFECTIVE EXPECTATIONS
Ashoush NN1, Ellithy MA2, EL Shahat KM3, Ahmed EM4, Abdelsalam MS4
1Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt, 2Faculty of Medicine, Ain Shams University, Cairo, Egypt, 3Faculty of Medicine. Alazhar University, Cairo, Egypt, 4International Medical Center., Cairo, Egypt

PCN40
B13
TREATMENT PATTERNS IN NON-SMALL CELL LUNG CANCER IN FRANCE
Klein AB1, Wang H1, Shire N1, Chalubert H2, Alessandrini ER2, Descoins S2, Medina P2
1AstraZeneca, Gaithersburg, MD, USA, 2Kantar Health, Paris, France

PCN41
B14
ESTIMATING THE NUMBER OF RELAPSED AND REFRACTORY INDOLENT LYMPHOMA PATIENTS ACROSS EUROPE, WHO ARE EXPECTED TO INITIATE A NEW LINE OF THERAPY (LOT)
Ellis H1, Neves C1, Chapman A1, Jeyakumaran D2
1BresMed, Sheffield, UK, 2Janssen Pharmaceuticals, High Wycombe, UK

PCN42
B15
TREATMENT PATTERNS IN HEAD & NECK SQUAMOUS CELL CANCER IN FRANCE: ARTISTE STUDY ON CANCEROLOGY PATIENT CHARTS
Klein AB1, Wang H1, Shire N1, Chalubert H2, Alessandrini ER2, Descoins S2, Medina P2
1AstraZeneca, Gaithersburg, MD, USA, 2Kantar Health, Paris, France

PCN43
B16
ORAL ESTROGEN THERAPY IS ASSOCIATED WITH REDUCED RISK OF HEPATITIS B VIRUS–RELATED HEPATOMA IN TAIWANESE POSTMENOPAUSAL WOMEN
Hsu HY
China Medical University Hospital, Taichung, Taiwan

PCN44
B17
CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS TREATED FOR RELAPSED REFRACTORY MULTIPLE MYELOMA OVER 3 YEARS: PREMIERE STUDY
Méndez I1, Zagorska A2, Artime E1, Lefevre C2, San José B1, González García P3, Martin-Regueira P3, Qizilbash N1
1OXON Epidemiology, Madrid, Spain, 2Bristol-Myers Squibb, Paris, France, 3Bristol-Myers Squibb, Madrid, Spain

PCN45
B18
EPIDEMIOLOGY OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN THE US, EUROPE AND JAPAN
Bharmal M, Guenther S, Kearney M, Kempel-Waibel A
Merck KGaA, Darmstadt, Germany

PCN46
B19
A SYSTEMATIC LITERATURE REVIEW OF UK EPIDEMIOLOGY OF BRCA1 AND BRCA2-MUTATED LOCALLY ADVANCED OR METASTATIC OVARIAN CANCER
Bedel DJ1, Ricci V2, Sarri G3, Lavaud V1
1Clovis Oncology, Sachseln, Switzerland, 2Evidera Ltd., London, UK, 3Evidera, London, UK

PCN47
B20
ESTIMATING POPULATION TRENDS IN COLORECTAL CANCER STRATIFIED BY STAGE, LINE OF THERAPY, AND HIGH MICROSATELLITE INSTABILITY IN THE UNITED STATES FROM 2017 TO 2021
Kobayashi MG1, Crooke HR1, Nwokeji ED2, Laurie M3, Kamble S3, Masood A4, Korytowsky B2
1PAREXEL International, Durham, NC, USA, 2Bristol-Myers Squibb, Lawrence Township, NJ, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4Saint Lukes Cancer Institute, University of Missouri Kansas City, Kansas City, MO, USA

PCN48
B21
INCIDENCE OF NON-SMALL-CELL LUNG CANCER AND BURDEN OF EGFR MUTATIONS: A 10-YEAR GLOBAL FORECAST
Ayodele O, Zhang N
Decision Resources Group, Burlington, MA, USA

PCN49
B22
USE OF ANTIPSYCHOTICS AND THE RISK OF COLORECTAL CANCER: A CASE-CONTROL STUDY USING DATA FROM THE LINKED NETHERLANDS CANCER REGISTRY AND PHARMO DATABASE NETWORK POPULATION
Kuiper JG1, van Herk-Sukel MP2, Lemmens VE3, Herings RM4
1Erasmus University Medical Center, Rotterdam, The Netherlands, 2University Medical Center Utrecht, Utrecht, The Netherlands, 3Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 4PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PCN50
B23
UNDERSTANDING MORTALITY IN MULTIPLE MYELOMA (MM): FINDINGS FROM AN OBSERVATIONAL CHART REVIEW OF DECEASED PATIENTS IN THE UK, FRANCE, GERMANY, ITALY AND SPAIN
Mohty M1, Raab MS2, Gonzalez-McQuire S3, Fink L4, Schoen P3, Biedermann P3, Cavo M5, Mateos M6
1Hôpital Saint-Antoine, Paris, France, 2University of Heidelberg, Heidelberg, Germany, 3Amgen (Europe) GmbH, Zug, Switzerland, 4Kantar Health, Paris, France, 5Bologna University School of Medicine, Bologna, Italy, 6University Hospital of Salamanca/Institute for Biomedical Research of Salamanca, Salamanca, Spain

PCN51
B24
CONTRASTING IMPROVING RATES OF CANCER SURVIVAL IN THE CONTEXT OF LIFE YEARS LOST COMPARED TO THE GENERAL POPULATION
Ward T, Gordon J, Bennett Wilton H, Medland S, McEwan P
Health Economics and Outcomes Research Ltd, Cardiff, UK

PCN52
B25
BASELINE POPULATION CHARACTERISTICS AND THE ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Kulakova M1, Hashim M1, Pfeiffer B2, Postma M3, Heeg B1
1Ingress Health, Rotterdam, The Netherlands, 2Merck KGaA, Darmstadt, Germany, 3University of Groningen, Groningen, The Netherlands

PCN53
B26
THE VALIDITY OF OBJECTIVE RESPONSE RATE AS A SURROGATE FOR PROGRESSION-FREE AND OVERALL SURVIVAL IN THE EVALUATION OF FIRST-LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
Goring SM1, Briggs A2, Penrod JR3, Fan S1, Waser N1, Thompson J4, Wilson JB1, Wang S1, Korytowsky B3, Chirita O5, Hertel N5, Yuan Y3
1ICON PLC, Vancouver, BC, Canada, 2Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4ICON PLC, Abingdon, UK, 5Bristol-Myers Squibb, Uxbridge, Middlesex, UK

PCN54
B27
ESTIMATING SURVIVAL AFTER RADICAL PROSTATECTOMY IN PROSTATE CANCER; A PROPENSITY-SCORE MATCHING METHOD
Brodszky V1, Varga P2, Gimesi-Országh J2, Fadgyas-Freyler P2, Nyirády P3, Boncz I4, Gulácsi L1
1Corvinus University of Budapest, Budapest, Hungary, 2National Health Insurance Fund of Hungary, Budapest, Hungary, 3Semmelweis University, Budapest, Hungary, 4University of Pécs, Pécs, Hungary

PCN55
C1
OVERALL SURVIVAL IN PATIENTS WITH METASTATIC UROTHELIAL CANCER BY FIRST-LINE THERAPY
Vander Velde NS1, Guerin A2, Ionescu-Ittu R2, Shi S2, Wu E3, Lin S4, de Ducla S5, Wang J4, Li S4, Derleth C4, Leppert JT6, Liu S1, Shi L1
1Tulane University School of Medicine, New Orleans, LA, USA, 2Analysis Group, Inc., Montreal, QC, Canada, 3Analysis Group, Boston, MA, USA, 4Genentech, Inc., South San Francisco, CA, USA, 5F. Hoffmann-La Roche Ltd., Basel, Switzerland, 6Veteran’s Affairs Palo Alto Health Care System, Palo Alto, CA, USA and Stanford University, Palo Alto, CA, USA

PCN56
C2
THE NOVEL GENERATION AND VALIDATION OF SURVIVAL CURVES IN ONCOLOGY UTILIZING ELECTRONIC MEDICAL RECORDS LINKED TO POINT OF SERVICE CLAIMS DATA
Wade RL1, Korytowsky B2, Singh P2, Dev P1, Bobiak S2, Cariola P1
1QuintilesIMS, Plymouth Meeting, PA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA

PCN57
C3
SURVIVAL RATES IN PRIMARY HEPATIC CARCINOMA PATIENTS WITH CIRRHOSIS IN SOUTH KOREA: A RETROSPECTIVE ANALYSIS OF 68,328 PATIENTS IN THE NATIONAL CANCER REGISTRY
Yang J1, Choi I1, Suh J2, Tchoe H3, Shin S4
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea, Republic of (South), 2National Evidence based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South), 3National Evidence-based Healthcare Collaborating Agency(NECA), Seoul, Korea, Republic of (South), 4National Evidence based Health-care Collaborating Agency, Seoul, Korea, Republic of (South)

PCN58
C4
PREDICTING OUTCOMES FROM MULTIPLE UNCONTROLLED HISTORICAL STUDIES OF TREATMENT OF PHYSICIAN’S CHOICE: PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN UNTREATED METASTATIC MERKEL CELL CARCINOMA
Hatswell AJ1, Cooper M1, Bharmal M2, Bullement A1
1BresMed Health Solutions, Sheffield, UK, 2Merck KGaA, Darmstadt, Germany

PCN59
C5
MATCHING ADJUSTED INDIRECT COMPARISON OF SUNITINIB AND EVEROLIMUS FOR THE TREATMENT OF PANCREATIC NEUROENDOCRINE TUMOURS (PNETS)
Ishak J1, Rael M2, Hicks M3, Mittal S3, Eatock M4, Valle JW5
1Evidera, Montreal, QC, Canada, 2Evidera, San Francisco, CA, USA, 3Pfizer UK, Tadworth, Surrey, UK, 4Belfast Health and Social care Trust, Belfast, UK, 5The Christe NHS, Manchester, UK

CANCER - Cost Studies
PCN60
C6
FINANCIAL IMPACT OF INTRODUCING SC TRASTUZUMAB (HERCEPTIN) VERSUS CURRENTLY USED IV TRASTUZUMAB (HERCEPTIN) ON THE BUDGETS OF DIFFERENT HOSPITALS ACROSS KINGDOM OF SAUDI ARABIA (KSA)
N A1, Ali A2, AL-Tweigeri T3, Zekri J4, Awad N5, Safwat M5, Narang A6, Goyal R7
1King Khalid National Guard Hospital, Jeddah, Saudi Arabia, 2King Fahad Medical City, Riyadh, Saudi Arabia, 3King Faisal Specialist Hospital, Riyadh, Saudi Arabia, 4King Faisal Specialist Hospital, Jeddah, Saudi Arabia, 5QuintilesIMS, Dubai, United Arab Emirates, 6QunitilesIMS, Gurugram, India, 7QuintilesIMS, Thane, India

PCN61
C7
BUDGET IMPACT ANALYSIS OF DABRAFENIB AND TRAMETINIB COMBINATION THERAPY IN THE TREATMENT OF BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER IN THE UNITED STATES
Zhou Z1, Bensimon A2, Cheng J2, Dalal A3
1Analysis Group, Inc., London, UK, 2Analysis Group, Inc., Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN62
C8
BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
Mistry R1, Suri G1, Young KC1, Hettle R1, May JR1, Brixner D2, Oderda G2, Biskupiak J2, Tang D3, Bhattacharyya D4, Bhattacharyya S4, Mishra D4, Dalal A3
1PAREXEL International, London, UK, 2Milcreek Outcomes Group, Salt Lake City, UT, USA, 3Novartis, East Hanover, NJ, USA, 4Novartis, Hyderabad, Telangana, India

PCN63
C9
BUDGET IMPACT MODEL OF COBIMETINIB IN COMBINATION WITH VEMURAFENIB FOR PREVIOUSLY UNTREATED BRAF V600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
Kyriopoulos D1, Athanasakis K1, Akratos A2, Theodoropoulou F2, Caporis X2, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2Roche (Hellas) S.A., Athens, Greece

PCN64
C10
BUDGET IMPACT ANALYSIS OF FIRST-LINE CERITINIB IN THE TREATMENT OF ALK+ METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UNITED STATES
Mutebi A1, Zhou Z2, Ricculli ML3, Han S3, Xie J4, Dalal A1, Culver K1
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Analysis Group, Inc., London, UK, 3Analysis Group, Inc., Boston, MA, USA, 4Analysis Group, Inc., New York, NY, USA

PCN65
C11
ECONOMIC BURDEN ASSOCIATED WITH SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES IN COLOMBIA
Pérez M1, Garcia Perlaza J2, Fletscher P1, Juan V3
1Amgen Biotecnológica SAS, Bogotá, Colombia, 2Amgen Intercontinental Region, Bogotá, Colombia, 3Econopharma Consulting, DF, Mexico

PCN66
C12
BUDGET IMPACT ANALYSIS OF TRIFLURIDINE AND TIPIRACIL HYDROCHLORIDE IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN GREECE
Gourzoulidis G1, Kourlaba G1, Petrakis D2, Souglakos I3, Pentheroudakis G2, Maniadakis N4
1Evroston LP, Athens, Greece, 2Department of Oncology, University of Ioannina Medical School, Ioannina, Greece, 3Laboratory of Tumor Cell Biology, Faculty of Medicine, University of Crete, Department of Medical Oncology, University Hospital of Heraklion, Crete, Greece, 4National School of Public Health, Athens, Greece

PCN67
C13
BUDGET IMPACT OF ATEZOLIZUMAB FOR THE TREATMENT OF 2ND LINE NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE WITH PLATINUM CONTAINING CHEMOTHERAPY IN GREECE
Kourkoulas N, Kyriopoulos D, Athanasakis K
National School of Public Health, Athens, Greece

PCN68
C14
BUDGET IMPACT OF ALECTINIB IN THE TREATMENT OF NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GREECE
Kourkoulas N, Kyriopoulos D, Athanasakis K
National School of Public Health, Athens, Greece

PCN69
C15
TO DETERMINE THE FINANCIAL IMAPCT OF INTRODUCING SC RITUXIMAB (MABTHERA) VS. CURRENTLY USED IV RITUXIMAB (MABTHERA) ON THE BUDGETS OF DIFFERENT HOSPITALS ACROSS THE KINGDOM OF SAUDI ARABIA (KSA)
Rauf M1, Dada R2, Awad N3, Safwat M3, Narang A4, Goyal R5
1King Faisal Specialist Hospital, Riyadh, Saudi Arabia, 2King Faisal Specialist Hospital, Jeddah, Saudi Arabia, 3QuintilesIMS, Dubai, United Arab Emirates, 4QunitilesIMS, Gurugram, India, 5QuintilesIMS, Thane, India

PCN70
C16
BUDGET IMPACT ANALYSIS OF AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN THE US
Bharmal M1, D'Angelo SP2, Phatak H3
1Merck KGaA, Darmstadt, Germany, 2Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3EMD Serono, Billerica, MA, USA

PCN71
C17
FINANCIAL CONSEQUENCES OF THE PERFORMANCE OF A PD-L1 TEST TO SELECT PATIENTS RECEIVING SECOND AND THIRD LINE TREATMENTS FOR NON-SMALL CELL LUNG CANCER IN ITALY
Restelli U1, Artale S2, Pacelli V1, Croce D1
1LIUC University, Castellanza, Italy, 2Presidio Ospedaliero di Gallarate ASST - Valle Olona, Gallarate, Italy

PCN72
C18
PREDICTING THE FUTURE COSTS OF CANCER BASED ON REGISTER DATA AND INNOVATION TRENDS
Bugge C1, Sæther EM1, Kristiansen IS2
1Oslo Economics, Oslo, Norway, 2University of Oslo, Oslo, Norway

PCN73
C19
HEALTHCARE COSTS ASSOCIATED WITH CERVICAL CANCER, PRECANCEROUS LESIONS, AND GENITAL WARTS TREATMENT IN TAIWAN
Tang C1, Jiang J1, You S2, Cheng W3
1Taipei Medical University, Taipei, Taiwan, 2Fu-Jen Catholic University, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan

PCN74
C20
THE ECONOMIC IMPACT OF SWITCHING TO HERCEPTIN (TRASTUZUMAB) BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A UK PAYER PERSPECTIVE
Brown D, Bozkaya D
Xcenda, LLC, Palm Harbor, FL, USA

PCN75
C21
PHARMACOECONOMIC ASPECTS OF VARIOUS STRATEGIES OF VESSEL SEALING AND REDUCTION OF POSTOPERATIVE COMPLICATIONS OF INGUINAL LYMPH NODES DISSECTION IN PATIENTS WITH GYNECOLOGIC CANCERS
Ryazhenov VV1, Gorokhova SG2, Maximkin S3
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Research Clinical Center of JSC Russian Railways, Moscow, Russia, 3Center for strategic research in healthcare, Moscow, Russian Federation

PCN76
C22
COST-EFFECTIVENESS AND BUDGET IMPACT OF NEW THERAPIES FOR METASTATIC MELANOMA IN ITALY
Pompilio G1, Campanella P2, Integlia D1
1ISHEO Srl, Roma, Italy, 2ISHEO Srl, Rome, Italy

PCN77
C23
PUBLICATION TIMING AND DATA UTILISATION IN COST-EFFECTIVENESS ANALYSES IN NON-SMALL CELL LUNG CANCER – A LITERATURE ANALYSIS ON PUBLICATION TIMING
Lam N, Lukose A, Rouwette TP, van den Broek R
Excerpta Medica, Amsterdam, The Netherlands

PCN78
C24
AN ECONOMIC EVALUATION MODEL FOR FOLLICULAR LYMPHOMA (FL): PREDICTING TREATMENT COST, LIFE EXPECTANCY AND QUALITY-ADJUSTED LIFE YEAR OF DIFFERENT SCENARIOS USING UK POPULATION BASED OBSERVATIONAL DATA
Wang H1, Aas E2, Smith A1, Roman E1, Crouch S1, Burton C3, Patmore R4
1University of York, York, UK, 2University of Oslo, Oslo, Norway, 3Leeds Teaching Hospitals NHS Trust, Leeds, UK, 4Castle Hill Hospital, Hull, UK

PCN79
C25
THE COST STUDY OF CETUXIMAB AND PANITUMUMAB IN THE FIRST-LINE TREATMENT OF MCRC IN THE CZECH REPUBLIC
Hradecka I1, Rihova B1, Demlova R2
1Masaryk University, Brno, Czech Republic, 2Masaryk Memorial Cancer Institute, Brno, Czech Republic

PCN80
C26
IDENTIFICATION OF GENERIC CANCER MEDICINES THAT HAVE UNDERGONE MOMENTOUS PRICE RISES IN THE NHS IN ENGLAND
Garcia Sanchez JJ, Harries M
MAP BioPharma Limited, Cambridge, UK

PCN81
C27
WITHDRAWN

PCN82
D1
WITHDRAWN

PCN83
D2
COST OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB AS FIRST LINE TREATMENT IN ADVANCED MELANOMA ACROSS VARIOUS EUROPEAN MARKETS
Ovcinnikova O1, Bourhis F2, Shah M3, Potluri R4, Chirita O5, Sabater J6, Di Rienzo P7
1Mapi, London, UK, 2Mapi (an ICON plc company), Nanterre, France, 3Mapi, Lexington, KY, USA, 4SmartAnalyst Inc., New York, NY, USA, 5Bristol-Myers Squibb, Uxbridge, Middlesex, UK, 6Bristol-Myers Squibb, Madrid, UK, 7Bristol Myers Squibb, Rome, Italy

PCN84
D3
COST IMPACT OF PROTOCOL COMPLIANCE FOR CANCER TREATMENT PLANS IN THE PRIVATE HEALTHCARE ENVIRONMENT
Kotzé L
Isimo Health, Cape Town, South Africa

PCN85
D4
TRABECTEDIN VERSUS PAZOPANIB WITHIN THE TREATMENT OF ADVANCED, METASTATIC, LEIOMYOSARCOMAS IN SCOTLAND: RESULTS OF A COST-EFFECTIVENESS ANALYSIS FOLLOWING A MATCHING ADJUSTED INDIRECT COMPARISON
Fernandez JM1, Garcia San Andrés B2
1Pharmamar SA, Colmenar Viejo, Spain, 2Pharmamar, Colmenar Viejo, Spain

PCN86
D5
SOCIETAL COSTS OF ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN IN THE UNITED KINGDOM
Bermingham S1, Schmid P2, Forster F3, Cornic L3, Theti D4, Smith A4
1Symmetron Ltd, Toronto, ON, Canada, 2Barts Cancer Institute, Queen Mary University of London, London, UK, 3Symmetron Ltd, Elstree, UK, 4Pfizer Ltd, Surrey, UK

PCN87
D6
COST BURDEN ASSOCIATED WITH ADVANCED NON-SMALL CELL LUNG CANCER (A-NSCLC): IMPACT OF DISEASE STAGE
Wood R1, Taylor-Stokes G1, Lees M2, Chirita O3
1Adelphi Real World, Macclesfield, UK, 2Bristol-Myers Squibb, Rueil Malmaison, France, 3Bristol-Myers Squibb, Uxbridge, Middlesex, UK

PCN88
D7
WITHDRAWN

PCN89
D8
ESTIMATION OF THE COST OF METASTATIC MELANOMA IN FRANCE USING MELBASE DATA
Kandel M1, Allayous C2, Dalle S3, Dalac S4, Saiag P5, Lacour J6, Descamps V7, Maubec E7, Lesimple T8, Stoebner P9, Arnault J10, Dupuy A11, Stephan A12, Guillot B13, Dreno B14, Ballon A2, Lebbe C2, Borget I15
1INSERM DR Paris 11, Villejuif, France, 2Saint-Louis Hospital, Paris, France, 3Hospices Civils de Lyon Hospital, Cancer research center of Lyon, Lyon, France, 4Dijon Hospital, Dijon, France, 5Ambroise Pare Hospital, Boulogne Billancourt, France, 6Nice Hospital, Nice, France, 7Bichat Hospital, Paris, France, 8CLCC Rennes Eugene Marquis, Rennes, France, 9Nîmes Hospital, Nîmes, France, 10Amiens Hospital, Amiens, France, 11Rennes Hospital, Rennes, France, 12Caen Hospital, Caen, France, 13Montpellier Hospital, Montpellier, France, 14Centre Hospitalier Universitaire, Nantes Cedex 1, France, 15Gustave Roussy, Villejuif, France

PCN90
D9
ASSESSING THE HEALTHCARE COST OF DIABETIC NON-SMALL CELL LUNG CANCER PATIENTS COMPARED TO NON-SMALL CELL LUNG CANCER PATIENTS
Ruban C1, Blanchette CM2, Howden R3, Kowalkowski M4, Marino J1, Saunders W5
1University of North Carolina Charlotte, Charlotte, NC, USA, 2Precision Health Economics, Davidson, NC, USA, 3University of North Carolina at Charlotte, Charlotte, NC, USA, 4Levine Cancer Institute, Charlotte, NC, USA, 5UNC Charlotte College of Health and Human Services – Health Informatics, Charlotte, NC, USA

PCN91
D10
COSTS ASSOCIATED WITH DISEASE PROGRESSION IN ADVANCED MELANOMA - A CLAIMS ANALYSIS USING A NOVEL STAGING ALGORITHM
Song J1, Goldschmidt D2, Driver M1, Buchanan J3, Murugappan S4
1Analysis Group, Inc., Los Angeles, CA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Amgen Inc., South San Francisco, CA, USA, 4Amgen Inc., Thousand Oaks, CA, USA

PCN92
D11
REAL LIFE COST OF TREATMENT AND FOLLOW-UP IN PANCREATIC ADENOCARCINOMA PATIENTS TREATED AT THE ANTWERP UNIVERSITY HOSPITAL (UZA), BELGIUM
De Paepe A1, Van den Eede N1, Strens D2, Specenier P3
1University of Antwerp, Antwerpen, Belgium, 2Realidad bvba, Grimbergen, Belgium, 3Antwerp University Hospital, Edegem, Belgium

PCN93
D12
BURDEN OF HOSPITALIZATIONS RELATED TO SPINAL TUMORS IN FRANCE: EVOLUTION BETWEEN 2012 AND 2014
Brasseur P1, de Léotoing L2, Fernandes J3, Tournier C2, Jouaneton B2, Vainchtock A2
1Medtronic plc, Tolochenaz, Switzerland, 2HEVA, LYON, France, 3Oc-Santé, Montpellier, France

PCN94
D13
THE ECONOMIC BURDEN OF BREAST CANCER IN RUSSIA
Ignatyeva V, Derkach EV, Avxentyeva M, Omelyanovskiy VV
The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation

PCN95
D14
RETROSPECTIVE ANALYSIS OF HOSPITAL EPISODE STATISTICS DATA TO ESTIMATE THE ECONOMIC BURDEN OF VAGINAL AND VULVAL CANCER IN ENGLAND (2009-2015)
Chatterjee A1, Matthews I2, Stephens S1
1Pharmerit International, York, UK, 2Merck Sharp & Dohme Limited, Maidenhead, UK

PCN96
D15
ECONOMIC BURDEN OF GASTRIC CANCER IN TURKEY
Bilici A1, Gumus M1, Malhan S2, Oksuz E2, Oksuzoglu B3, Yalcın S4
1Medipol University, Istanbul, Turkey, 2Baskent University, Ankara, Turkey, 3Ankara Oncology Training and Research Hospital, Ankara, Turkey, 4Hacettepe University, Ankara, Turkey

PCN97
D16
TREATMENT COST OF HEPATOCELLULAR CARCINOMA FROM THE HEALTH INSURANCE’S PERSPECTIVE IN VIET NAM
Phan TT1, Nguyen TT2, Dinh HY1
1Medicine and Pharmacy University, Ho Chi Minh City, Viet Nam, 2University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam

PCN98
D17
COST OF ILNESS ANALYSIS: A COMPARISON OF THE COSTS OF DRUG THERAPY FOR PATIENTS WITH PROSTATE CANCER, BREAST CANCER, COLON CANCER, MELANOMA AND RENAL CELL CARCINOMA IN MOSCOW
Poliakova K1, Ermolaeva T1, Holownia M1, Bashlakova E1, Khachanova N1, Andreev D1, Pokatilo A1, Byakhov M2, Davydovskaya M1
1State Budgetary Institution of Moscow City "Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Healthcare", Moscow, Russian Federation, 2Moscow City Health Department, Moscow, Russian Federation

PCN99
D18
LABOUR PRODUCTIVITY LOSSES ASSOCIATED WITH BREAST CANCER: AN ANALYSIS ALONG A DECADE IN SPAIN
Oliva-Moreno J, Peña-Longobardo LM
University of Castilla-La Mancha, Toledo, Spain

PCN100
D19
RESOURCE USE AND HEALTH-CARE COSTS OF CHRONIC LYMPHOCYTIC LEUKEMIA IN SLOVAKIA
Ondrusova M1, Suchansky M1, Chudej J2, Psenkova M3
1Pharm-In Ltd, Bratislava, Slovak Republic, 2University hospital Martin, Martin, Slovak Republic, 3Pharm-In Ltd, Bratislava, Slovakia

PCN101
D20
ANNUAL COSTS OF BEST SUPPORTIVE CARE FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN GERMANY
Mathes J1, Kern B2, Kotowa W1
1IGES Institut GmbH, Nuremberg, Germany, 2IGES Institut GmbH, Berlin, Germany

PCN102
D21
PRICE-DOSE RELATIONSHIP: THE CASE OF ORAL ONCOLOGY DRUGS IN EU5
Czira A1, Pacheco L2, Teale CW3
1GfK, London, UK, 2GfK UK, London, UK, 3GfK UK Limited, Melton Mowbray, UK

PCN103
D22
DOES CCG SPENDING ON CANCER AFFECT OUTCOMES IN BREAST AND LUNG CANCER?
Gray P1, Squirrell D2
1OPEN Access Consulting (an OPEN Health Company), London, UK, 2Open Health, London, UK

PCN104
D23
A SYSTEMATIC REVIEW OF THE HEALTH-RELATED QUALITY OF LIFE AND COSTS IN DIFFUSE LARGE B-CELL LYMPHOMA
Chadda S1, Nelson L1, Podlogar S2, Garside J3, Upton CM1
1SIRIUS Market Access, London, UK, 2Janssen Global Oncology, Raritan, NJ, USA, 3Janssen, High Wycombe, UK

PCN105
D24
REAL-WORLD DATA ANALYSIS OF CANCER TREATMENT COST DRIVERS BY TYPE AND PLACE OF SERVICE
Scott J, Alcorn C, Garofalo D, Montgomery J
Integra Connect, West Palm Beach, FL, USA

PCN106
D25
ESTIMATING THE DRUG TREATMENT COST OF BREAST CANCER
Berghuis AS1, Koffijberg H1, Terstappen LW1, Sleijfer S2, IJzerman MJ1
1University of Twente, Enschede, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands

PCN107
D26
LANDSCAPE OF MALIGNANT MELANOMA: THE IMPACT OF UPCOMING THERAPIES
Bento MJ1, Raimundo A1, Sousa J2, Valadas F2, Rocha-Gonçalves FN1
1IPO Porto, Porto, Portugal, 2QuintilesIMS, Porto Salvo, Portugal

PCN108
D27
CLINICAL AND ECONOMIC HISTORY OF THE ONCOLOGICAL PATIENT AT THE END OF LIFE
Hernandez E1, Perez-Carrascosa FM2, Navarro-Espigares JL1, Rodriguez Barrrios J3, Ruiz-Centeno FJ1, Exposito-Hernandez J1
1HOSPITAL VIRGEN DE LAS NIEVES, GRANADA, Spain, 2FIBAO, GRANADA, Spain, 3Daiichi Sankyo Europe GmbH, Munich, Germany

PCN109
E1
REAL-WORLD HEALTH CARE RESOURCE UTILIZATION AND RELATED COSTS AMONG PATIENTS WHO RECEIVED AT LEAST TWO LINES OF TREATMENT FOR ADVANCED NSCLC IN ENGLAND, THE NETHERLANDS, AND SWEDEN
Solem CT1, Penrod JR2, Lees M3, Macahilig C4, Luo L1, Verleger K5, Manley Daumont M6, Hertel N7
1Pharmerit International, Bethesda, MD, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb, Rueil Malmaison, France, 4Medical Data Analytics, Parsippany, NJ, USA, 5Pharmerit International, Berlin, Germany, 6Bristol-Myers Squibb, Paris, France, 7Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK

PCN110
E2
HEALTHCARE COSTS OF IPILIMUMAB IN PATIENTS WITH ADVANCED CUTANEOUS MELANOMA IN DUTCH CLINICAL PRACTICE
Franken M1, Leeneman B2, Jochems A3, Schouwenburg M3, Aarts M4, van Akkooi A5, van den Berkmortel F6, van den Eertwegh A7, de Groot J8, van der Hoeven J9, Hospers G10, Kapiteijn E11, Koornstra R12, Kruit W13, Louwman M14, Piersma D15, van Rijn R16, Suijkerbuijk K17, ten Tije A18, Vreugdenhil G19, Wouters M5, van Zeijl M3, Haanen J5, Uyl - de Groot C1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands, 3Dutch Institute for Clinical Auditing, Leiden, The Netherlands, 4Maastricht University Medical Center, Maastricht, The Netherlands, 5Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 6Zuyderland Medical Center Geleen-Heerlen, Heerlen, The Netherlands, 7VU University Medical Center, Amsterdam, The Netherlands, 8Isala Oncological Center, Zwolle, The Netherlands, 9Radboud university medical center, Amsterdam, The Netherlands, 10University Medical Center Groningen, Groningen, The Netherlands, 11Leiden University Medical Center, Leiden, The Netherlands, 12Radboud university medical center, Nijmegen, The Netherlands, 13ErasmusMC Cancer Institute, Rotterdam, The Netherlands, 14Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 15Medical Spectrum Twente, Enschede, The Netherlands, 16Medical Center Leeuwarden, Leeuwarden, The Netherlands, 17University Medical Center Utrecht, Utrecht, The Netherlands, 18Amphia Hospital, Breda, The Netherlands, 19Maxima Medical Center, Veldhoven, The Netherlands

PCN111
E3
COST DRIVERS OF LUNG CANCER CARE: RESULTS FROM A RETROSPECTIVE CHART REVIEW OF PRETREATED ADVANCED NSCLC PATIENTS IN EUROPE
Solem CT1, Penrod JR2, Lees M3, Macahilig C4, Luo L1, Verleger K5, Manley Daumont M6, Hertel N7
1Pharmerit International, Bethesda, MD, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb, Rueil Malmaison, France, 4Medical Data Analytics, Parsippany, NJ, USA, 5Pharmerit International, Berlin, Germany, 6Bristol-Myers Squibb, Paris, France, 7Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK

PCN112
E4
COST ANALYSIS OF LUNG CANCER IN CHINA
GAO T1, Chen B2, Guan H1, Liu GG3
1PKU China Center for Health Econimic Research, Beijing, China, 2Beijing Medical and Health Economic Research Association, Beijing, China, 3National School of Development, Peking University, Beijing, China

PCN113
E5
COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CARCINOMA IN PORTUGAL
Pinheiro BA1, Alarcão J1, Silva Miguel L1, Huang M2, Chandwani S2, Vargas Lopes F3, Borges M1
1Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 2Merck & Co., Inc., North Wales, PA, USA, 3MSD, Paço de Arcos, Portugal

PCN114
E6
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN THREE EUROPEAN COUNTRIES USING 28-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
Hirst A1, Paly VF2, Diamantogiannis F3, Guilmet C4, Polanco S C5, Sabater J6, Chirita O7
1Mapi Group, London, UK, 2ICON, New York, NY, USA, 3Bristol-Myers Squibb Hellas, Athens, Greece, 4MAPI Group, Nanterre, France, 5Bristol-Myers Squibb Madrid, Madrid, Spain, 6Bristol-Myers Squibb, Princeton, NJ, USA, 7Bristol-Myers Squibb, Uxbridge, Middlesex, UK

PCN115
E7
A POPULATION-BASED STUDY ON CLINICAL OUTCOMES AND MEDICAL COSTS OF LAPAROSCOPIC VERSUS OPEN SURGERY FOR COLON CANCER PATIENTS IN TAIWAN
Wu Y1, Tan EC2, Yang M1
1National Taiwan University, Taipei, Taiwan, 2Ministry of Health and Welfare, Taipei, Taiwan

PCN116
E8
EVALUATING ADVERSE EVENTS COSTS IN CANCER PATIENTS IN LEBANON FROM TWO PAYERS PERSPECTIVE
El Hashem G1, Becker RV2, Maskineh C1
1CCHO-SAL, Beirut, Lebanon, 2Russell Becker Consulting, Chicago, IL, USA

PCN117
E9
COST-EFFECTIVENESS ANALYSIS OF ALECTINIB COMPARED TO CHEMOTHERAPY FOR THE TREATMENT OF TREATMENT-NAÏVE PATIENTS WITH ALK POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN GREECE
Kourkoulas N, Kyriopoulos D, Athanasakis K
National School of Public Health, Athens, Greece

PCN118
E10
THE CLINICAL AND COST EFFECTIVENESS OF DASATINIB VERSUS NILOTINIB FOR THE FIRST AND SECOND LINE TREATMENT OF PEOPLE WITH CHRONIC MYELOID LEUKAEMIA
Ward T1, Jones B1, Harrison JP2, Hurst M1, Tyas D2, McEwan P1, Gordon J1
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Bristol-Myers Squibb, Uxbridge, UK

PCN119
E11
COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED/METASTATIC BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE
Hettle R1, Suri G1, Mistry R1, Chandiwana D2, Lee A3
1PAREXEL International, London, UK, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Pharmaceuticals UK Limited, Surrey, UK

PCN120
E12
THE COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF PEOPLE WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT AND BRENTUXIMAB VEDOTIN
Jones B1, Ward T1, Harrison JP2, Hurst M1, Tyas D2, McEwan P1, Gordon J1
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Bristol-Myers Squibb, Uxbridge, UK

PCN121
E13
A HEALTH TECHNOLOGY ASSESSMENT OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ADDED TO INTERVAL CYTOREDUCTIVE SURGERY IN STAGE III OVARIAN CANCER
Retèl VP1, van Lieshout C1, Koole S1, Sikorska K1, Sonke GS1, van Driel WJ1, van Harten WH2
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Twente, Enschede, The Netherlands

PCN122
E14
COST EFFECTIVENESS ANALYSIS (CEA) OF NIVOLUMAB IN 2ND LINE NON-SMALL CELL LUNG CANCER (NSCLC) WITH NON-SQUAMOUS HISTOLOGY (NSQ) USING A MIXED COMPARATOR OF DOCETAXEL AND PEMETREXED IN AN AUSTRALIAN SETTING
Donvovan L, Kim H
Bristol-Myers Squibb Australia, Mulgrave, Australia

PCN123
E15
COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB FOR UNTREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN PORTUGAL
Saramago P1, Ines M2, Saraiva F2
1University of York, York, UK, 2Pfizer Portugal, Lisbon, Portugal

PCN124
E16
COST EFFECTIVENESS ANALYSIS OF EXEMESTANE VERSUS CAPECITABINE MONOTHERAPY FOR PATIENTS WITH HORMONE RECEPTOR–POSITIVE AND HER2-NEGATIVE, METASTATIC BREAST CANCER FROM NATIONAL CANCER INSTITUTE PRESPECTIVE IN EGYPT
Abdallah H1, Abourawash AS1, Elgazzar M2, Helal A2
1CAPA, Ministry of Health and Population, Cairo, Egypt, 2National Cancer Institute (NCI), Cairo University, Cairo, Egypt

PCN125
E17
ECONOMIC EVALUATION OF TRIFLURIDINE AND TIPIRACIL HYDROCHLORIDE IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN GREECE
Gourzoulidis G1, Kourlaba G1, Petrakis D2, Souglakos I3, Pentheroudakis G2, Maniadakis N4
1Evroston LP, Athens, Greece, 2Department of Oncology, University of Ioannina Medical School, Ioannina, Greece, 3Laboratory of Tumor Cell Biology, Faculty of Medicine, University of Crete, Department of Medical Oncology, University Hospital of Heraklion, Crete, Greece, 4National School of Public Health, Athens, Greece

PCN126
E18
THE COST AND OUTCOMES OF BREAST CANCER SCREENING FOR WOMEN 40-49 YEARS OLD IN RUSSIA
Ignatyeva V, Derkach EV, Avxentyeva M, Omelyanovskiy VV, Boyarskaya T
The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation

PCN127
E19
COST-EFFECTIVENESS OF AFATINIB VERSUS ERLOTINIB FOR THE TREATMENT OF SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE AFTER A FIRST-LINE PLATINIUM BASED THERAPY
Pignata M1, Le Lay K2, Luciani L3, McConnachie C4, Gordon J5, Chouaid C6, Roze S1
1HEVA HEOR Sarl, Lyon, France, 2Boehringer Ingelheim France, Paris, France, 3Boehringer-Ingeleheim France, Paris, France, 4Ossian Health Economics and Communications, Basel, Switzerland, 5Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 6Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France

PCN128
E20
TREATMENT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS IN MACEDONIA: DEVELOPMENT OF COST-EFFECTIVENESS ANALYSIS
Qerimi V1, Kapedanovska-Nestorovska A2, Sterjev Z2, Genadieva-Stavric S3, Suturkova L2
1UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/ Faculty of Pharmacy, UKIM - Skopje, Macedonia, Hall i.T., Austria, 2Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia, 3University St Cyril and Methodius - Skopje, Macedonia, Skopje, Macedonia, The former Yugoslav Republic of

PCN129
E21
COST-EFFECTIVENESS OF PONATINIB IN THE TREATMENT OF PATIENTS WITH CHRONIC PHASE- CHRONIC MYELOID LEUKEMIA IN GREECE
Gourzoulidis G1, Kourlaba G1, Giannoulia P2, Panagiotidis P3, Maniadakis N4
1Evroston LP, Athens, Greece, 2Evangelismos General Hospital, Athens, Greece, 3Laiko General Hospital, Athens, Greece, 4National School of Public Health, Athens, Greece

PCN130
E22
TREATMENT FOR CERVIX UTERI CANCER: COST-EFFECTIVENESS ANALYSIS IN A DEVELOPING COUNTRY CONTEXT
Sat-Muñoz D1, Balderas-Peña L2, Ortiz-Gonzalez F2, Chagollán-Ramírez J3, Chávez-Hurtado J4, Avalos-Nuño J5, Bañuelos-Rizo M1, Cortes-Torres E2, Palos-Delgadillo H3
1Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, 2UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico, 3Universidad de Guadalajara. Centro Universitario de Ciencias Económico Administrativas, Zapopan, Jalisco, Mexico, 4Universidad de Guadalajara, Zapopan, Mexico, 5UMAE Hospital de Gineco-Obstetricia Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico

PCN131
E23
COST EFFECTIVENESS OF FULVESTRANT 500 MG IN ENDOCRINE THERAPY-NAÏVE WOMEN WITH HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN THE UK
Livings C1, Jones N2, Bertranou E3, Large S3, Phelps H3, Ekman M4, Telford C5
1AstraZeneca, Luton, UK, 2AstraZeneca, Cambridge, UK, 3PAREXEL Access, London, UK, 4AstraZeneca, Södertälje, Sweden, 5AstraZeneca, Gaithersburg, MD, USA

PCN132
E24
AN EMPIRICAL ANALYSIS OF THE ROLE OF LEARNING BY DOING IN DYNAMIC COST-EFFECTIVENESS
Incerti D1, Peneva D1, Shrestha A1, Ramaswamy K2, Smith G2, Stevens W1
1Precision Health Economics, Los Angeles, CA, USA, 2Pfizer, Inc., New York, NY, USA

PCN133
E25
COST EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
Suri G1, Mistry R1, Young KC1, Hettle R1, May JR1, Brixner D2, Oderda G2, Biskupiak J2, Tang D3, Bhattacharyya D4, Bhattacharyya S4, Mishra D4, Dalal A3
1PAREXEL International, London, UK, 2Milcreek Outcomes Group, Salt Lake City, UT, USA, 3Novartis, East Hanover, NJ, USA, 4Novartis, Hyderabad, Telangana, India

PCN134
WITHDRAWN

PCN135
E26
COST-EFFECTIVENESS OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) COMPARED WITH NIVO AND IPI MONOTHERAPIES IN THE FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN THE UNITED STATES: ANALYSIS USING 28-MONTH OVERALL SURVIVAL (OS) DATA FROM CHECKMATE 067
Baker T1, Paly VF1, Sabater J2, Gupte-Singh K2, Beyhaghi H2, Kotapati S2, Rao S2, Briggs A3
1ICON, New York, NY, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3University of Glasgow, Glasgow, Scotland, UK

PCN136
E27
COST-EFFECTIVENESS OF PONATINIB IN THE TREATMENT OF PATIENTS WITH ACCELERATED OR BLAST PHASE - CHRONIC MYELOID LEUKEMIA IN GREECE
Gourzoulidis G1, Kourlaba G1, Giannoulia P2, Panagiotidis P3, Maniadakis N4
1Evroston LP, Athens, Greece, 2Evangelismos General Hospital, Athens, Greece, 3Laiko General Hospital, Athens, Greece, 4National School of Public Health, Athens, Greece

PCN137
F1
PHARMACOECONOMIC ANALYSIS OF ENZALUTAMIDE AND ABIRATERONE FOR TREATMENT OF CHEMOTHERAPY-NAÏVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Avxentyev NA1, Frolov M2
1Research Institute of Finance, Ministry of Finance of the Russian Federation and Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia, 2Volgograd State Medical University of the Ministry of Health Russian Federation and Interregional Association of Clinical Pharmacologists, Volgograd, Russia

PCN138
F2
THE IMPACT OF TREATMENT-FREE REMISSION OF TASIGNA® FOR CML PATIENTS IN CHINA – A COST EFFECTIVENESS ANALYSIS
Chen S1, Xuan JW2, Zhang Y3, Zhu H4, Luo J5, Tan J1, Liu C6, Qiu M7, Qu S8, Xiong T7
1The First Affiliated Hospital of Soochow University, Suzhou, China, 2Sun Yat-sen University, Guangzhou, China, 3Henan Cancer Hospital, Zhengzhou, China, 4West China Hospital, Sichuan University, Chengdu, China, 5The Second Hospital of Hebei Medical University, Shijiazhuang, China, 6Novartis Pharmaceuticals (China) Oncology, Beijing, China, 7IMS Health China, Shanghai, China, 8IQVIA, Shanghai, China

PCN139
F3
COST-EFFECTIVENESS ANALYSIS OF HAPLOIDENTICAL VS MATCHED UNRELATED ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN PATIENTS OLDER THAN 55 YEARS
Debals-Gonthier M1, Siani C2, Faucher C3, Touzani R4, Lemarie C3, Chabannon C3, Furst S3, Devillier R3, Caymaris L3, Blaise D3, Le Corroller Soriano A4
1Aix-Marseille University, Marseille, France, 2ISPB, Faculte de Pharmacie, Lyon, France, University Lyon 1, University of Lyon, Lyon, France, 3Institut Paoli-Calmettes, Marseille, France, 4INSERM, Marseille, France

PCN140
F4
THE COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN LYMPHOMA AND INCREASED RISK OF RELAPSE
Ringkvist J, Engstrom A
Takeda Sweden, Solna, Sweden

PCN141
F5
COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN PORTUGAL
Almeida J1, Vandewalle B1, Félix J1, Amorim A2, Henriques J2, Wang-Silvanto J3, Haffemayer B3, Branscombe N3
1Exigo Consultores, Lisboa, Portugal, 2Servier Portugal, Lisboa, Portugal, 3Les Laboratoires Servier, Suresnes, France

PCN142
F6
TECHNICAL CHALLENGES IN COST-EFFECTIVENESS ANALYSIS FOR ONCOLOGY TREATMENTS: IDENTIFYING FREQUENT ISSUES IN MODELLING FROM NICE PERSPECTIVE
Czira A1, Pacheco L2, Teale CW3
1GfK, London, UK, 2GfK UK, London, UK, 3GfK UK Limited, Melton Mowbray, UK

PCN143
F7
A LITERATURE REVIEW OF HEALTH ECONOMIC ASSESSMENTS, HEALTH CARE RESOURCE UTILIZATION (HCRU), AND HEALTH RELATED QUALITY-OF-LIFE (HRQOL) IN PATIENTS WITH GASTRIC CANCER (GC)
van Dalfsen N1, Contente M2, Gudala K3, Lee D1, Maglinte G4, Calvo E5
1BresMed Health Solutions Ltd., Sheffield, UK, 2Bristol-Myers Squibb, Uxbridge, Middlesex, UK, 3BresMed Health Solutions Ltd., Gurugram, India, 4Bristol-Myers Squibb, Princeton, NJ, USA, 5START Madrid, Centro Integral Oncologico Clara Campal, Madrid, Spain

PCN144
F8
PHARMACOECONOMIC MODELLING IN THE EARLY HEALTH TECHNOLOGY ASSESSMENT OF GENERIC PEGYLATED LIPOSOMAL DOXORUBICIN
Krysanov I1, Ermakova V2, Tiapkina M2
1Institute of Medical and Social Technologies, Moscow National University of Food Production, Moscow, Russia, 2Sechenov First Moscow State Medical University, Moscow, Russian Federation

PCN145
F9
PHARMACOECONOMIC ANALISYS OF TRASTUZUMAB EMTANZINE IN PATIENTS WITH METASTATIC BREAST CANCER AND CENTRAL NERVOUS SYSTEM METASTASES
Kolbin A1, Kurylev A1, Balykina Y2, Proskurin M2
1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2Saint Petersburg State University, Saint Petersburg, Russia

PCN146
F10
HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS’ ACCESS TO PATIENTS
Bucher D1, Abalan M1, Allou A1, Dumon L1, Vialard L1, Troubat A2, Maurel F1
1QuintilesIMS, La Défense Cedex, France, 2QuintilesIMS, Paris La Défense, France

PCN147
F11
A SYSTEMATIC REVIEW OF PHARMACOECONOMIC EVALUATION OF ERLOTINIB IN THE FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Nguyen TT1, Grappasonni I2, Nguyen TB3, Petrelli F2
1Hanoi University of Pharmacy, Hanoi, Vietnam, 2University of Camerino, Camerino, Italy, 3Hanoi University of Pharmacy, Hanoi, Viet Nam

PCN148
F12
PHARMACOECONOMIC ANALISYS OF OBINUTUZUMAB PLUS CHLORAMBUCIL IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA AND COEXISTING CONDITIONS
Kolbin A1, Vilum I1, Balykina Y2, Proskurin M2
1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2Saint Petersburg State University, Saint Petersburg, Russia

PCN149
F13
COST-EFFECTIVENESS OF PONATINIB IN THE TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ ALL), SUITABLE FOR ALLOGENEIC STEM CELL TRANSPLANT, IN GREECE
Vellopoulou K1, Kourlaba G1, Giannoulia P2, Panagiotidis P3, Maniadakis N4
1EVROSTON LP, Athens, Greece, 2Evangelismos General Hospital, Athens,, Greece, 3Laiko General Hospital, Athens, Greece, 4National School of Public Health, Athens, Greece

PCN150
F14
COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO THE STANDARD OF CARE FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY IN GREECE
Kourkoulas N, Kyriopoulos D, Athanasakis K
National School of Public Health, Athens, Greece

PCN151
F15
PROSPECTIVE ASSESSMENT OF THE ACCURACY, RELIABILITY AND COST-EFFECTIVENESS OF STAGING NON-SMALL CELL LUNG CANCER (NSCLC) ONLY WITH THE COMBINATION OF PET/CT AND BRAIN MRI
Gkogkozotou V1, Gkiozos I1, Syrigos K2
13rd Department of Medicine, Sotiria General Hospital, Athens, Greece, 2Athens Medical School, Sotiria General Hospital, Athens, Greece

PCN152
F16
COST EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FROM HEALTH CARE SYSTEM PERSPECTIVE IN EGYPT.
Elkony MA1, Elsisi GH2
1central administration of pharmaceutical affairs, Ministry of health and population, Cairo, Egypt, 2Central Administration for Pharmaceutical Affairs (CAPA), Ministry of Health and Population, Cairo, Egypt

PCN153
F17
COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS GEFITINIB IN EGFR-MUTATED POPULATION WITH ADVANCED NON-SMALL-CELL LUNG CANCER IN FRANCE
de Pouvourville G1, Luciani L2, Le Lay K2, PO P3, Bennouna J4, Perol M5, Moro-Sibilot D6, Vergnengre A7, Chouaid C8
1ESSEC Business School, Cergy-Pontoise, France, 2Boehringer-Ingeleheim France, Paris, France, 3CRLCC François Baclesse, Caen,, France, 4CHU Nantes, Nantes, France, 5Centre Léon Bérard, Lyon, France, 6CHU Grenoble, Grenoble, France, 7CHU de Limoges, Limoges, France, 8Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France

PCN154
F18
THE CHOICE OF EFFECTIVENESS CRITERIA AFFECTS CONCLUSIONS OF ECONOMIC EVALUATION OF HEALTH CARE INNOVATIONS: EXAMPLE BASED ON A RANDOMISED MULTICENTER TRIAL COMPARING TWO REDUCED INTENSITY CONDITIONING REGIMEN (FLU-BU-ATG) VS. (FLU-TBI) FOR MATCHED RELATED ALLOGENEIC STEM CELLS TRANSPLANTATION.
Le Corroller Soriano A1, Siani C2, Tabrizi R3, Bay J4, Boher J5, Faucher C5, Blaise D5
1Aix-Marseille University, Marseille, France, 2ISPB, Faculte de Pharmacie, Lyon, France, University Lyon 1, University of Lyon, Lyon, France, 3CHU Bordeaux, Pessac, France, 4CHU de Clermont-Ferrand - Hôpital d'Estaing, Clermont-Ferrand, France, 5Institut Paoli-Calmettes, Marseille, France

PCN155
F19
COST EFFECTIVENESS OF NIVOLUMAB FOR PATIENTS WITH ADVANCED, PREVIOUSLY TREATED RENAL CELL CARCINOMA IN SCOTLAND
Mahon S1, Bullement A2, Willis A2, Sullivan W2, Britton JA2, Cox L2, Tyas D3, Sowdani A3
1BresMed Ireland, Dublin 24, Ireland, 2BresMed Health Solutions, Sheffield, UK, 3Bristol-Myers Squibb, Uxbridge, UK

PCN156
F20
THE IMPACT OF INCREASE IN THE PROPORTION OF EARLY BREAST CANCER CASES ON COSTS AND OUTCOMES
Ignatyeva V, Avxentyeva M, Derkach EV, Omelyanovskiy VV, Boyarskaya T
The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation

PCN157
F21
ECONOMIC EVALUATION OF EXEMESTANE VERSUS TAMOXIFEN IN POST-MENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM THE EGYPTIAN HEALTH CARE SYSTEM PERSPECTIVE
Elshafei zA, Abourawash AS, Elsisi GH
central adminstrationof pharmaceutical affairs-ministry of health, Cairo, Egypt

PCN158
F22
PHARMACOECONOMIC ANALISYS OF IXABEPILONE MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER RESISTANT TO ANTHRACYCLINES, TAXANES AND CAPECITABINE
Kolbin A1, Mosikian A1, Kurylev A1, Balykina Y2, Proskurin M2
1First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russia, 2Saint Petersburg State University, Saint Petersburg, Russia

PCN159
F23
THE COMPARATIVE COST-EFFECTIVENESS OF CABOZANTINIB, EVEROLIMUS AND AXITINIB IN ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY: SCOTTISH PERSPECTIVE
Lister J1, Vataire A2, Amzal B3, Dinet J2, Meng J4, Karcher H3, Gabriel S2
1Analytica LASER, Lörrach, Germany, 2Ipsen Pharma, Boulogne-Billancourt, France, 3Analytica Laser, London, UK, 4LASER Analytica, Lorrach, Germany

PCN160
F24
COST-EFFECTIVENESS OF AFATINIB, GEFITINIB, ERLOTINIB, AND PEMETREXED-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENTS FOR EGFR MUTATION POSITIVE, ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
Zhu J1, Ye M2, Fu J2, Wu B3, Chu Y4, Zhao Y5, Zhang Y4, Kuo D5, Su B6
1Shanghai Chest Hospital, Shanghai Jiaotong University, shanghai, China, 2Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, shanghai, China, 3Shanghai Jiaotong University, Shanghai, China, 4Boehringer Ingelheim (China) Investment Co., Ltd., Beijing, China, 5Boehringer Ingelheim China Investment Co., Ltd., Shanghai, China, 6Boston Healthcare, shanghai, China

PCN161
F25
THE COST-EFFECTIVENESS OF LIVER TRANSPLANTATION COMPARED TO CHEMOTHERAPY FOR NON-RESECTABLE LIVER-ONLY METASTASES AFTER COLORECTAL CANCER (MCRC).
Bjørnelv GW1, Dueland S1, Line P1, Joranger P2, Fretland Å1, Edwin B1, Sorbye H3, Aas E4
1Oslo University Hospital, Oslo, Norway, 2Oslo and Akershus University College of Applied Sciences, Oslo, Norway, 3University of Bergen, Bergen, Norway, 4University of Oslo, Oslo, Norway

PCN162
F26
COST-EFFECTIVENESS IN ENGLAND OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY
Lister J1, Vataire A2, Amzal B3, Dinet J2, Meng J4, Karcher H3, Gabriel S2
1Analytica LASER, Lörrach, Germany, 2Ipsen Pharma, Boulogne-Billancourt, France, 3Analytica Laser, London, UK, 4LASER Analytica, Lorrach, Germany

PCN163
F27
COST-EFFECTIVENESS OF IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN ENGLAND
Hassan F1, Peng S2, Dorman E2, Sorensen S2, Thompson G1, Lee J1
1Janssen UK, High Wycombe, UK, 2Evidera, Bethesda, MD, USA

PCN164
G1
COST-EFFECTIVENESS OF NILOTINIB VERSUS DASATINIB FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP), RESISTANT OR INTOLERANT TO IMATINIB, IN FRAME OF RUSSIAN HEALTHCARE SYSTEM
Goyert N1, Tran D1, Efremova E2, Apostopoulos C3, Grima D1
1Cornerstone Research Group, Burlington, ON, Canada, 2Novartis Pharma LLC, Moscow, Russian Federation, 3Novartis Pharma AG Switzerland, Basel, Basel-City, Switzerland

PCN165
G2
ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA
Quon P1, Xiao Y2, Sorensen S1, Schultz M3, Tahami Monfared AA3
1Evidera, Bethesda, MD, USA, 2Evidera Inc., London, UK, 3Bristol-Myers Squibb, Montreal, QC, Canada

PCN166
G3
MODELLING THE EFFECTIVENESS OF IBRUTINIB VERSUS PHYSICIAN’S CHOICE (PC) IN RELAPSED OR REFRACTORY (RR) WALDENSTRÖM’S MACROGLOBULINEMIA (WM) WITHIN ENGLAND
Guillermin A1, Hassan F1, Sydnor S1, Peng S2, Proskorovsky I3, Sorensen S2, Thompson G1, Lee J1
1Janssen UK, High Wycombe, UK, 2Evidera, Bethesda, MD, USA, 3Evidera, Montreal, QC, Canada

PCN167
G4
COST-EFFECTIVENESS OF AFATINIB AND ERLOTINIB AS SECOND-LINE TREATMENTS FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG IN CHINA
Zhu J1, Ye M2, Fu J2, Wu B3, Chu Y4, Zhao Y5, Zhang Y4, Kuo D5, Su B6
1Shanghai Chest Hospital, Shanghai Jiaotong University, shanghai, China, 2Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, shanghai, China, 3Shanghai Jiaotong University, Shanghai, China, 4Boehringer Ingelheim (China) Investment Co., Ltd., Beijing, China, 5Boehringer Ingelheim China Investment Co., Ltd., Shanghai, China, 6Boston Healthcare, shanghai, China

PCN168
G5
RISK-STRATIFIED BREAST CANCER SCREENING AND NON-ADHERENCE IN GERMANY
Arnold M1, Quante A2
1LMU Munich, Munich, Germany, 2Helmholtz Zentrum München, Neuherberg, Germany

PCN169
G6
VALUE COMMUNICATION STRATEGIES FOR IMMUNOTHERAPIES IN NSCLC: A QUICK EVIDENCE ASSESSMENT FROM THE UK
Kamra S, Sehgal M, Bamrara A, Takyar J, Takyar S, Pandey V
PAREXEL International, Chandigarh, India

PCN170
G7
COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB IN HEAVILY PRE-TREATED MULTIPLE MYELOMA PATIENTS FOR THE ITALIAN HEALTHCARE SYSTEM
Lo Muto R1, Lenzi M1, Franzini JM2, Baggi A2, Bonetti G2, Hegenbarth A2
1Janssen, Cologno Monzese, Italy, 2Business Integration Partners, Milano, Italy

PCN171
G8
COST-EFFECTIVENESS OF ADDITIONAL HUMAN PAPILLOMAVIRUS VACCINATION PROGRAMMES, IN THE NETHERLANDS
Setiawan D1, Westra TA2, Daemen T3, Nijman HW3, Wilschut JC3, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2GlaxoSmithKline, Zeist, The Netherlands, 3University Medical Center Groningen, Groningen, The Netherlands

PCN172
G9
SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+ BREAST CANCER PATIENTS: A MONTENEGRIN COST-MINIMIZATION ANALYSIS
Todorovic V1, Durutovic I1, Ivanovska A2, Zajmovic A2
1Clinical Center Montenegro, Podgorica, Montenegro, 2Hoffmann La Roche Ltd., Podgorica, Montenegro

PCN173
G10
WITHDRAWN

PCN174
G11
ECONOMIC EVALUATION OF DASATINIB COMPARED TO NILOTINIB AS SECOND LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN GREECE
Gourzoulidis G1, Vassilopoulos G2, Gialama F1, Kourlaba G1, Diamantogiannis F3, Maniadakis N4
1Evroston LP, Athens, Greece, 2University of Thessaly Medical School, Larissa, Greece, 3Bristol-Myers Squibb Hellas, Athens, Greece, 4National School of Public Health, Athens, Greece

PCN175
G12
EXPANDED ACCESS TO PEMBROLIZUMAB FROM COST-SAVINGS GENERATED BY BIOSIMILAR FILGRASTIM (BIOSIM-FIL) IN THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED (FEBRILE) NEUTROPENIA (CIN/FN): SIMULATION STUDY
McBride A1, Balu S2, Campbell K2, Bikkina M2, MacDonald K3, Abraham I4
1University of Arizona Cancer Center, Tucson, AZ, USA, 2Sandoz, Inc., Princeton, NJ, USA, 3Matrix45, LLC, Tucson, AZ, USA, 4University of Arizona, Tucson, AZ, USA

PCN176
G13
COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT CONTAINING CRIZOTINIB FOR NON SMALL CELL LUNG CANCER (ALK+) PATIENTS
Sabater Cabrera E1, Puente J2, Oyagüez I3, García-Campelo R4, Reguart N5, Rodriguez D6, Cobo M7, Soto J8, Moran M8
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 2Hospital Clinico San Carlos, Madrid, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Pozuelo de Alarcón, Spain, 4hospital Universitario A Coruña, A Coruña, Spain, 5Hospital Clinic de Barcelona, Barcelona, Spain, 6Complejo Hospitalario Universitario Insular- Materno Infantil, Las Palmas de Gran Canaria, Spain, 7Hospital Regional de Malaga (Carlos Haya), Malaga, Spain, 8Pfizer Spain, Alcobendas, Spain

PCN177
G14
COST UTILITY ANALYSIS (CUA) OF NIVOLUMAB COMPARED TO EVEROLIMUS FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (RCC) IN AUSTRALIA
Liew D1, Patten N2, Tan M2, Kim H2
1Monash University, Melbourne, Australia, 2Bristol-Myers Squibb Australia, Mulgrave, Australia

PCN178
G15
COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN: ANALYSIS USING 28-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
Baker T1, Paly VF1, Sabater J2, Holmberg C3, Hultberg M4, Lundström J3, Minacori R5, Chirita O6
1ICON, New York, NY, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb, Bromma, Sweden, 4PAREXEL International, Stockholm, Sweden, 5PAREXEL International, London, UK, 6Bristol-Myers Squibb, Uxbridge, Middlesex, UK

PCN179
G16
A COST-UTILITY ANALYSIS COMPARING TWO SEQUENCES OF TREATMENT FOR FIRST-LINE CHEMOTHERAPY IN METASTATIC PROSTATE CANCER (MCRPC): CABAZITAXEL FOLLOWED BY DOCETAXEL VERSUS DOCETAXEL FOLLOWED BY CABAZITAXEL
Schwager M1, Fizazi K1, Zaghdoud N1, Delva R2, Gravis Mescam G3, Baciarello G1, Theodore C4, Gross Goupil M5, Bompas E6, Joly F7, Tazi Y8, L'Haridon T9, N'guyen T10, Barthelemy P11, Culine S12, Berdah J13, Deblock M14, Beuzedoc P15, Flechon A16, Cheneau C17, Martineau G1, Borget I1
1Gustave Roussy, Villejuif, France, 2ICO Paul Papin, Angers, France, 3Institut Paoli-Calmettes, Marseille, France, 4Hôpital Foch, Suresnes, France, 5CHU Bordeaux, Bordeaux, France, 6ICO Centre René Gauducheau, Saint-Herblain, France, 7Centre François Baclesse, Caen, France, 8Clinique Sainte-Anne, Strasbourg, France, 9CHD Vendée, La Roche Sur Yon, France, 10CHRU Besançon, Besançon, France, 11CHRU Strasbourg, Strasbourg, France, 12Hôpital Saint Louis, Paris, France, 13Clinique Sainte-Marguerite, Hyères, France, 14Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France, 15Institut Curie, Paris, France, 16Centre Léon Bérard, Lyon, France, 17CHRU Brest, Brest, France

PCN180
G17
WITHDRAWN

PCN181
G18
POTENTIAL THERAPEUTIC AND ECONOMIC VALUE OF RISK-STRATIFIED TREATMENT AS INITIAL TREATMENT OF MULTIPLE MYELOMA IN EUROPE
Gaultney JG1, Ng T1, Uyl-de Groot CA2, Sonneveld P3, van Beers EH4, van Vliet MH4, Redekop WK2
1Mapi Group, London, UK, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Erasmus MC, Rotterdam, The Netherlands, 4SkylineDx, Rotterdam, The Netherlands

PCN182
G19
PHASE I/II BASED EARLY ECONOMIC EVALUATION OF ACALABRUTINIB FOR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Vreman RA1, Geenen JW1, Goettsch WG2, Hovels AM1, Leufkens HG1, Al MJ3
1Utrecht University, Utrecht, The Netherlands, 2The National Healthcare Institute (ZIN), Diemen, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands

PCN183
G20
ADD-ON THERAPY IN BREAST CANCER - PROBABILITY OF COST-EFFECTIVENESS IN ECONOMIC ANALYSES
Prząda-Machno P1, Marzec M2, Borowiack E2, Nowotarska A2, Jarosz J2, Szczuka A1, Konopka-Pliszka M1
1Pfizer LCC, Warsaw, Poland, 2NUEVO HTA CLP, Cracow, Poland

PCN184
G21
WITHDRAWN

PCN185
G22
COST UTILITY ANALYSIS OF SINGLE FRACTION VERSUS MULTIPLE FRACTION RADIOTHERAPY IN PATIENTS WITH PAINFUL BONE METASTASES; AN IRANIAN PATIENT'S PERSPECTIVE STUDY
Bayazidi Y1, Keshtkaran A2, Homaie Rad E3, Ansari M2, Javanbakht M2, Hashemi Meshkini A1, Nikfar S1, Zaboli P4
1Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 2Shiraz University of Medical Sciences, Shiraz, Iran (Islamic Republic of), 3Guilan University of Medical Sciences, Rasht, Iran (Islamic Republic of), 4Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of)

PCN186
G23
SELECTIVE INTERNAL RADIOTHERAPY (SIRT) IN METASTATIC COLORECTAL CANCER PATIENTS WITH LIVER METASTASES: PRELIMINARY PRIMARY CARE RESOURCE USE AND UTILITY RESULTS FROM THE FOXFIRE RANDOMISED CONTROLLED TRIAL.
Fusco F1, Wolstenholme J1, Gray A1, Chau I2, Dunham L3, Love S4, Roberts A5, Moschandreas J4, Virdee P4, Lewington V6, Wilson G7, Khan N8, Francis A3, Wasan H9, Sharma R10
1Health Economics Research Centre - University of Oxford, Oxford, UK, 2Royal Marsden Hospital, London, UK, 3Oncology Clinical Trials Office - University of Oxford, Oxford, UK, 4Centre for Statistics in Medicine - University of Oxford, Oxford, UK, 5Addenbrooke’s Hospital, Cambridge Cancer Trials Centre, Cambridge, UK, 6Guy's Hospital, King's College London, London, UK, 7The Christie NHS Foundation Trust, Manchester, UK, 8Royal Marsden and Chelsea & Westminster Hospital,, London, UK, 9Imperial College Healthcare NHS Trust & Imperial College, London, UK, 10University College London; University of Oxford, London; Oxford, UK

PCN187
G24
ECONOMIC EVALUATION OF ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN PATIENTS WITH NONE/MILD SYMPTOMS AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY
Abotaleb A1, Saad AS2
1world health organization, cairo, Egypt, 2Ain Shams University, Cairo, Egypt

PCN188
G25
PHARMACOECONOMIC SYSTEMATIC EVALUATION OF BEVACIZUMAB TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
CHENG W, Chen W
Fudan University, Shanghai, China

PCN189
G26
HOSPITAL RESOURCE USE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) IN NATIONAL UNIVERSITY HOSPITALS IN JAPAN
Satoh T1, Ledesma DA2, Yoshihara N2
1Kitasato University School of Medicine, Kanagawa, Japan, 2Bayer Yakuhin, Ltd., Tokyo, Japan

PCN190
G27
CHARACTERIZING THE UTILIZATION OF THE TRILLIUM DRUG PROGRAM BY AN ONCOLOGY PATIENT POPULATION.
Cheng SY1, DeAngelis C2, Seung SJ3, Rahman F1, Chan K2, Earle C4, Mittmann N5
1Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 2Odette Cancer Centre, Toronto, ON, Canada, 3Sunnybrook Research Institute, Toronto, ON, Canada, 4Ontario Institute for Cancer Research, Toronto, ON, Canada, 5Cancer Care Ontario, Toronto, ON, Canada

PCN191
G28
COSTS OF GRADE 3 AND 4 ADVERSE EVENTS ASSOCIATED WITH CURRENT CANCER TREATMENTS - COST ESTIMATIONS FOR SWEDEN, NORWAY, FINLAND AND DENMARK
Lauppe R1, Carlqvist P2, Chavez B2, Lundqvist I2, Ohna A1, Widén J1
1Quantify Research, Stockholm, Sweden, 2Novartis Sweden, Täby, Sweden

PCN192
G29
RESOURCE USE AND ASSOCIATED COSTS OF MANAGING DOCETAXEL-RELATED NEUTROPENIC SEPSIS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN THE UK NHS: REVEAL-NS
Pulfer A1, Hodgson M2, Patel A2, Purchase J2, Summerhayes M2, Newsom-Davis T3
1pH Associates Ltd (an Open Health company), Marlow, UK, 2Roche Products Ltd, Welwyn Garden City, UK, 3Chelsea & Westminster Hospital, London, UK

PCN193
G30
ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR’S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
DeRosa M1, Cocks K2, Korytowsky B3, Contente M4, Taylor F1, Shaw JW3
1Adelphi Values, Boston, MA, USA, 2Adelphi Mill, Bollington, Cheshire, UK, 3Bristol-Myers Squibb, Lawrenceville, NJ, USA, 4Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, Middlesex, UK

PCN194
G31
RATE OF HOSPITALIZATION DUE TO ADVERSE EVENT AND LENGTH OF STAY FOR ATEZOLIZUMAB IN SECOND AND THIRD LINE METASTATIC NON-SMALL LUNG CANCER (NSCLC) USING PHASE 3 OAK STUDY
Paracha N1, Felizzi F2
1F. Hoffman-La Roche, Basel, Switzerland, 2F. Hoffmann La Roche, Basel, Switzerland

CANCER - Patient-Reported Outcomes & Patient Preference Studies
PCN195
G32
INDICATORS OF PARTICIPATION IN CERVICAL CANCER SCREENING AMONG ROMANY WOMEN
Pakai A1, Horváthné Kívés Z2, Szabó-Gabara K2, Oláh A2, Boncz I2, Csákvári T1, Karácsony I3, Vajda R2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Szombathely, Hungary

PCN196
G33
PREDICTING EQ-5D UTILITY INDEX SCORES FOR GASTRIC CANCER PATIENTS IN JAPAN: A PRELIMINARY MODEL
Pike J1, Maglinte G2, Rider A1, Cocks K3, Taylor F4, Contente M5, Calvo E6
1Adelphi Real World, Cheshire, UK, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Adelphi Values, Bollington, Cheshire, UK, 4Adelphi Values, Boston, MA, USA, 5Bristol-Myers Squibb, Uxbridge, Middlesex, UK, 6START Madrid, Centro Integral Oncologico Clara Campal, Madrid, Spain

PCN197
G34
COMPARISON OF UTILITY VALUES IMPLEMENTED IN DISEASE MODELS OF METASTATIC MELANOMA
Gorry C1, Barry M1, McCullagh L2
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College, Dublin, Ireland

PCN198
G35
MINIMAL IMPACT ON PATIENTS’ HEALTH UTILITIES ASSOCIATED WITH ADVERSE EVENTS IN METASTATIC MERKEL CELL CARCINOMA PATIENTS ON TREATMENT WITH AVELUMAB
Kaufman H1, Hunger M2, Hennessy M3, Schlichting M4, Bharmal M4
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, 2Mapi (an ICON plc company), Munich, Germany, 3EMD Serono, Billerica, MA, USA, 4Merck KGaA, Darmstadt, Germany

PCN199
H1
ESTIMATING UTILITIES / DISUTILITIES FOR HIGH RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) AND TREATMENT-RELATED ADVERSE EVENTS
Hall F1, de Freitas HM2, Kerr C1, Ito T1, Nafees B3, Lloyd AJ4, Penton J1, Hadi M2, Pham T5
1Janssen-Cilag, UK, High Wycombe, UK, 2Mapi Group, London, UK, 3Nafees Consulting, London, UK, 4Acaster Lloyd Consulting Limited, London, UK, 5Mapi Group, Boston, MD, USA

PCN200
H2
HEALTH STATE UTILITIES ASSOCIATED WITH TREATMENT OPTIONS FOR ACUTE MYELOID LEUKEMIA (AML)
Matza LS1, Deger K1, Howell T1, Hillgruber NK2, Yeager AM3, Hogge D4, Fisher V5, Louie AC5, Chung KC6
1Evidera, Bethesda, MD, USA, 2Moffitt Cancer Center, Tampa, FL, USA, 3University of Arizona Cancer Center, Tucson, AZ, USA, 4Gordon and Leslie Diamond Health Care Centre, Vancouver, BC, Canada, 5Jazz Pharmaceuticals, Inc, Palo Alto, CA, USA, 6Jazz Pharmaceuticals, Palo Alto, CA, USA

PCN201
H3
NO EQ-5D? ANALYSIS OF ALTERNATIVE UTILITY VALUE SOURCES USED IN NICE APPRAISALS FOR ONCOLOGY INDICATIONS
Beale RC1, Wickstead RM1, Chen G2, Walker E1, Griffiths M1
1Costello Medical Consulting Ltd, London, UK, 2Costello Medical Consulting Ltd, Cambridge, UK

PCN202
H4
FACTORS CONTRIBUTING TO THE CEILING EFFECT AMONG PATIENTS WITH PROSTATE CANCER WHO WERE JUDGED TO HAVE “FULL-HEALTH” BY EQ-5D-5L
Murasawa H1, Matsuoka Y2, Tanaka N3, Takeda Y1, Uchikawa S1, Noto S4, Shimozuma K1
1Ritsumeikan University, Kusatsu, Japan, 2Kagawa University, Kagawa, Japan, 3Nara Medical University, Kashihara, Japan, 4Niigata University of Health and Welfare, Niigata, Japan

PCN203
H5
UK UTILITY ELICITATION IN PATIENTS WITH FOLLICULAR LYMPHOMA
Wang H1, Smith A1, Yu G1, Aas E2, Bagguley T1, Howell D1, Roman E1, Burton C3, Patmore R4
1University of York, York, UK, 2University of Oslo, Oslo, Norway, 3Leeds Teaching Hospitals NHS Trust, Leeds, UK, 4Castle Hill Hospital, Hull, UK

PCN204
H6
MAPPING FROM SF-36 TRIAL DATA TO EQ-5D UTILITIES IN ADVANCED BASAL CELL CARCINOMA
Loughran T1, Reyes A2, Pletscher M2, Krivasi T2, Hatswell AJ3
1Hoffmann-La Roche Ltd., Welwyn Garden City, UK, 2Hoffmann-La Roche Ltd, Basel, Switzerland, 3BresMed Health Solutions, Sheffield, UK

PCN205
H7
QUALITY-ADJUSTED LIFE YEARS (QALYS) FOR INOTUZUMAB OZOGAMICIN VERSUS INVESTIGATORS CHOICE (IC) FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R B-ALL)
Batteson R1, Critchlow S1, Barnes A1, Glah D2, Smith A2, Lang K2, Su Y3
1BresMed, Sheffield, UK, 2Pfizer Ltd, Surrey, UK, 3Pfizer Inc, New York, NY, USA

PCN206
H8
UTILITY VALUES ACROSS LINES OF THERAPY IN IMMUNO-ONCOLOGY TREATMENTS: AN EXAMPLE FROM ADVANCED MELANOMA
Tilden D1, Sierakowski W1, Cottrell S1, Kim H2
1THEMA Consulting Pty Ltd, Pyrmont, Australia, 2Bristol-Myers Squibb Australia, Mulgrave, Australia

PCN207
H9
REPORTED UTILITIES FOR PATIENTS WITH UNTREATED ADVANCED/METASTATIC RENAL CELL CARCINOMA – A SYSTEMATIC LITERATURE REVIEW
Mudd A1, Bakker R1, Malcolm B2, Doan J3, Alleman CJ1
1Pharmerit International, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Uxbridge, UK, 3Bristol-Myers Squibb, Princeton, NJ, USA

PCN208
H10
CORRELATION ANALYSIS BETWEEN HEALTH STATE VALUES DERIVED FROM EQ-5D-5L AND EQ-VAS IN JAPANESE BREAST CANCER PATIENTS.
Iwatani T1, Noto S2, Tsugawa K1
1St.Marianna University School of Medicine, Kawasaki, Japan, 2Niigata University of Health and Welfare, Niigata, Japan

PCN209
H11
A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE AND TOXICITY (Q-TWIST) ANALYSIS COMPARING NIVOLUMAB AND THERAPY OF INVESTIGATOR’S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) (CHECKMATE 141)
Simpson S1, Cocks K1, Contente M2, DeRosa M3, Taylor F3, Shaw JW4
1Adelphi Mill, Bollington, Cheshire, UK, 2Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, Middlesex, UK, 3Adelphi Values, Boston, MA, USA, 4Bristol-Myers Squibb, Lawrenceville, NJ, USA

PCN210
H12
UTILITY META-REGRESSION; FREQUENTIST VS BAYESIAN APPROACHES IN MULTIPLE MYELOMA
Hatswell AJ1, Burns D1, Baio G2, Wadelin F3
1BresMed Health Solutions, Sheffield, UK, 2University College London, London, UK, 3Nottingham University Hospital, Nottingham, UK

PCN211
H13
HEALTH RELATED QUALITY OF LIFE IN CANCER IMMUNOTHERAPY: PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Purchase J1, Paracha N2, Abdulla A2
1Roche Products Ltd, Welwyn Garden City, UK, 2F. Hoffman-La Roche, Basel, Switzerland

PCN212
H14
QUALITATIVE EXPLORATION OF THE REAL-WORLD EXPERIENCES OF MEN RECEIVING OR REFUSING CHEMOTHERAPY (DOCETAXEL) FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Ito T1, Grant L2, Mills A3, Heselwood A3, Gater A2
1Janssen-Cilag, UK, High Wycombe, UK, 2Adelphi Values Ltd, Bollington, Cheshire, UK, 3Adelphi Research UK, Bollington, UK

PCN213
H15
PREFERENCES FOR SURVIVAL IN NON-SMALL CELL LUNG CANCER: SWINGING FOR HOME RUNS OR BASE HITS?
Hauber AB1, Penrod JR2, Gebben D1, Musallam L2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA

PCN214
H16
PATIENT EMPOWERMENT FOR HEALTHCARE DECISION-MAKING ASSESSING ONCOLOGY INNOVATION THROUGH MULTICRITERIA DECISION ANALYSIS
Aguarón A1, Fernández A2, Gimón A3, Nafria B4, Gaspar B5, Guarga L6, Gálvez M7, Fuentes M8, Saldaña R9, Badia X6
1Myeloma Patients Europe, Madrid, Spain, 2Spanish Association Against Cancer, Madrid, Spain, 3Spanish Breast Cancer Federation, Barcelona, Spain, 4Hospital Sant Joan de Déu, Barcelona, Spain, 5Spanish Affected Lung Cancer Association, Madrid, Spain, 6Omakase Consulting, Barcelona, Spain, 7Patient Association Platform, -, Spain, 8Spanish Melanoma, -, Spain, 9ACCU Confederation, Madrid, Spain

PCN215
H17
WHAT MATTERS TO SPANISH PATIENTS AND PHYSICIANS WHEN FACING DECISIONS FOR GEP-NET? AN EXPLORATION USING A REFLECTIVE MULTICRITERIA SHARED-DECISIONMAKING FRAMEWORK
Wagner M1, Samaha D2, Cuervo J3, Patel H1, Martinez M3, O'Neil WM1, Jiménez-Fonseca P4, Goetghebeur MM5
1Analytica LASER, Montreal, QC, Canada, 2Analytica LASER, London, UK, 3Analytica LASER, Madrid, Spain, 4Hospital Universitario Central de Asturias, Oviedo, Spain, 5Analytica LASER and School of Public Health, University of Montreal, Montreal, QC, Canada

PCN216
WITHDRAWN

PCN217
H18
PATIENT PREFERENCES REGARDING TREATMENT OPTIONS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
Bauer S1, Mueller S1, Ratsch B2, Pitura S2, Probst L2, van Eickels D2, Wilke T1
1Ingress-Health HWM GmbH, Wismar, Germany, 2Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany

PCN218
H19
PATIENT PREFENCES IN COLORECTAL ADENOMA SURVEILLANCE
McFerran E1, Boeri M1, McVicar D2, Kee F3
1Queens University Belfast, BELFAST, UK, 2QUEEN'S UNIVERSITY BELFAST, BELFAST, UK, 3Queen's University Belfast, Belfast, UK

PCN219
H20
IS WILLINGNESS TO PAY HIGHER FOR CANCER PREVENTION AND TREATMENT?
Shah K
Office of Health Economics, London, UK

PCN220
H21
PSYCHOLOGICAL IMPACT OF CANCER: MORE GOOD THAN BAD
Yao G1, Lai J2, Garcia S2, Yount S2, Cella D2
1National Taiwan University, Taipei, Taiwan, 2Northwestern University, Chicago, IL, USA

PCN221
H22
MOVING PRO MEASURES FROM THE PROMISE TO IMPACT IN ONCOLOGY CLINICAL PRACTICE: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW
Anatchkova M1, Skalicky AM1, Whiteley J2, Jagun D2, McHorney CA1, Donelson S2
1Evidera - Evidence, Value & Access by PPD, Bethesda, MD, USA, 2Genentech Inc., South San Francisco, CA, USA

PCN222
H23
PATIENT EXPERIENCE ASSESSMENTS IN ADVANCED GASTRIC, ESOPHAGEAL, AND GASTROESOPHAGEAL JUNCTION CANCER STUDIES
Morlock R1, Turnbull J2, Rhode T2, Hawryluk E2, Gwaltney C2, Paty J2, Holmstrom S3
1Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 2QuintilesIMS Consulting Services, New York, NY, USA, 3Astellas Pharma Europe, B.V., Leiden, The Netherlands

PCN223
H24
PRO-CTCAE IMPACT ON PAYER EVALUATIONS OF ONCOLOGIC THERAPIES: A QUALITATIVE RESEARCH STUDY
Masters ET1, Kaplan H2, Smith G3, Deal LS4
1Pfizer Inc., New York, NY, USA, 2Red Team Associates, Horsham, PA, USA, 3Pfizer, Inc., New York, NY, USA, 4Pfizer Inc., Collegeville, PA, USA

PCN224
H25
UNDERSTANDING PATIENTS’ ABILITY TO FUNCTION IN ORDER TO INFORM CLINICAL BENEFIT IN ONCOLOGY STUDIES
Karagiannis T1, Marquis P2, Petersen J1, Meyers O1, Chui SY1, Campbell AK1, Strzok S2, Pompilus F2, Piault E1
1Genentech, Inc., South San Francisco, CA, USA, 2Modus Outcomes, Newton, MA, USA

PCN225
H26
PRO INSTRUMENTS USED IN STUDIES OF SKIN CANCER SINCE 1960
Martin A
Crystallise Ltd., East Tilbury, UK

PCN226
H27
SYMPTOMS AND IMPACTS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: QUALITATIVE STUDY FINDINGS
Naidoo S1, Smith I1, Turnbull J2, Gwaltney C2, Hawryluk E2, Paty J2
1Astellas Pharma, Inc., Chertsey, UK, 2QuintilesIMS Consulting Services, New York, NY, USA

PCN227
H28
WITHDRAWN

PCN228
H29
IMPACT OF ISOCITRATE DEHYDROGENASE (IDH) STATUS ON THE PERFORMANCE STATUS AND QUALITY OF LIFE (QOL) OF GLIOBLASTOMA MULTIFORME (GBM) PATIENTS
Waller J1, Atkinson T1, Byrne K2
1Adelphi Real World, Manchester, UK, 2Adelphi Real World, Bollington, Cheshire, UK

PCN229
H30
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC COLORECTAL CANCER USING EQ-5D-5L
Ungari AQ1, Cintra MA1, Nunes AA2, Peria FM3
1Hospital of Clinics of Faculty of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil, 2University of São Paulo, Ribeirão Preto, Brazil, 3Ribeirão Preto School of Medicine, Ribeirão Preto, Brazil

PCN230
H31
QUALITY OF LIFE (QOL), FUNCTIONAL STATUS (FS), AND SURVIVAL IN TRIPLE NEGATIVE BREAST CANCER (TNBC): DISCORDANCE OF DEFINITIONS AMONG A TARGETED LITERATURE REVIEW AND STAKEHOLDER INTERVIEWS
White R1, Agashe VR2, Duhig A3, Floyd J3, Maiese BA3, Slaff S3
1Celldex Therapeutics, Hampton, FL, USA, 2Xcenda UK Ltd., London, FL, UK, 3Xcenda, LLC, Palm Harbor, FL, USA

PCN231
H32
HEALTH-RELATED QUALITY OF LIFE AFTER MAJOR LOWER EXTREMITY AMPUTATION DUE TO MUSCULOSKELETAL TUMORS
Repo JP1, Barner-Rasmussen I1, Roine RP2, Häkkinen A3, Blomqvist C1, Tukiainen EJ1
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Helsinki University Hospital and University of Eastern Finland, Helsinki, Finland, 3Department of Education and Science, Central Finland Health Care District, Jyväskylä, Finland, Jyväskylä, Finland

PCN232
H33
A QUALITATIVE INTERVIEW STUDY TO EXPLORE THE PATIENT EXPERIENCE OF LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER AND EXPLORE THE CONTENT OF PATIENT-REPORTED OUTCOME MEASURES
Degboe A1, Kitchen H2, Aldhouse NV2, Trigg A2, Herman JM3, Narang A3, Hodgin M3, Johnson C4, Halling K5
1AstraZeneca, Gaithersburg, MD, USA, 2DRG Abacus, Manchester, UK, 3Johns Hopkins University, Baltimore, MD, USA, 4University of Southampton, Southampton, UK, 5AstraZeneca, Molndal, Sweden

PCN233
H34
TREATMENT SATISFACTION AND BURDEN OF ILLNESS WITH ORAL VS INJECTABLE MULTIPLE MYELOMA THERAPY IN PATIENTS WITH NEWLY DIAGNOSED DISEASE (NDMM)
Romanus D1, DasMahapatra P2, Hoole M2, Lowe M2, Lawler E2, Curran C2, Campbell S1, Bell J3
1Takeda Pharmaceuticals International Co, Cambridge, MA, USA, 2PatientsLikeMe, Cambridge, MA, USA, 3Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

PCN234
H35
WORK PRODUCTIVITY IN HER2 POSITIVE BREAST CANCER: A COMPARISON OF PATIENTS ACROSS STAGES OF EARLY AND METASTATIC DISEASE.
Verrill M1, Schmid P2, Retzler J3, Smith AB3, Bottomley CJ4, Dando S5, Tran I5, Leslie I5, Wardley A6
1Northern Centre for Cancer Care, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK, 2Barts Cancer Institute, Queen Mary University of London, London, UK, 3York Health Economics Consortium Ltd, York, UK, 4pH Associates (an Open Health company), Marlow, UK, 5Roche Products Limited, Welwyn Garden City, UK, 6The Christie NHS Foundation Trust, Manchester, UK

PCN235
I1
THE HUMANISTIC BURDEN OF MICROSATELLITE INSTABILITY-HIGH (MSI-H) COLORECTAL CANCER (CRC) AND METASTATIC CRC (MCRC) PATIENTS TREATED WITH SUBSEQUENT LINE THERAPY: A SYSTEMATIC REVIEW
Kohn CG1, Nguyen E2, Miller JD2, Nwokeji E3, Laurie M3, Kamble S3, Khan T3, Masood A4, Korytowsky B3
1University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4Saint Lukes Cancer Institute, University of Missouri Kansas City, Kansas City, MO, USA

PCN236
I2
HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND DISEASE SYMPTOMS IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH LENVATINIB (LEN) OR SORAFENIB (SOR)
Vogel A1, Qin S2, Kudo M3, Hudgens S4, Yamashita T5, Yoon J6, Fartoux L7, Simon K8, Lopez C9, Sung M10, Dutcus C11, Kraljevic S12, Tamai T11, Grunow N4, Meier G11, Breder V13
1Hannover Medical School, Hannover, Germany, 2Nanjing Bayi Hospital, Nanjing, China, 3Kindai University Faculty of Medicine, Osaka, Japan, 4Clinical Outcomes Solutions, Tucson, AZ, USA, 5Kanazawa University Hospital, Kanazawa, Japan, 6Seoul National University Hospital, Seoul, Korea, Republic of (South), 7Hôpital Saint-Antoine, Paris, France, 8NZOZ Centrum, Badan Klinicznych, Wroclaw, Poland, 9Hospital Universitario Marques de Valdecilla, Santander, Spain, 10Tisch Cancer Institute at Mount Sinai, New York, NY, USA, 11Eisai Inc., Woodcliff Lake, NJ, USA, 12Eisai Co. Ltd., Hatfield, UK, 13FSBSI N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

PCN237
I3
HEALTHCARE PROFESSIONALS’ PREFERENCES FOR THE TREATMENT SELECTION OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): THE PRELIC STUDY
Boqué C1, Abad M2, Moreno C3, Agustin M2, Garcia-Goñi M4, Gabás C5, Lizan L5, Granados E6, Castro-Gomez A6
1Instituto Catalán de Oncología, Barcelona, Spain, 2Hospital Miguel Servet, Zaragoza, Spain, 3Hospital Santa Creu y Sant Pau, Barcelona, Spain, 4Universidad Complutense, Madrid, Spain, 5Outcomes 10, Universitat Jaume I, Castellon, Spain, 6Gilead Sciences, MADRID, Spain

PCN238
I4
ASSOCIATION BETWEEN TUMOUR LESION SIZE AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA TREATED WITH AVELUMAB
Kaufman H1, Mahnke L2, von Heydebreck A3, Bharmal M3
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, 2EMD Serono, Billerica, Boston, MA, USA, 3Merck KGaA, Darmstadt, Germany

PCN239
I5
SYMPTOM DETERIORATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CABOZANTINIB OR EVEROLIMUS
Marteau F1, Beaumont J2, Gabriel S1, Hankins M3, Mangeshkar M4, Williams P5, Cella D2
1Ipsen Pharma SAS, Boulogne-Billancourt Cedex, France, 2Northwestern University, Chicago, IL, USA, 3Mapi Group, London, UK, 4Exelixis, Inc., South San Francisco, CA, USA, 5Mapi, Patient-Centered Outcomes, Lyon, France

PCN240
I6
PATIENT’S JOURNEY THROUGH ACUTE MYELOID LEUKEMIA (AML): UNDERSTANDING AML’S HUMANISTIC IMPACT THROUGH AN INTERNATIONAL PATIENT-CENTRIC QUALITATIVE STUDY
Delbecque L1, Pantiri K1, Seo C2, Stroupe A2, Durno N3, Glynn K2, DAlessio DL4, Brandt P4, Lasch K2
1Pharmerit International, Rotterdam, The Netherlands, 2Pharmerit International, Newton, MA, USA, 3Pharmerit International, York, UK, 4Novartis Pharmaceuticals, East Hanover, NJ, USA

PCN241
I7
RELATION OF QLQ-C30 AND QLQ-CR29 HEALTH RELATED QUALITY OF LIFE SCALES AND BIOCHEMICAL INDICATORS OF NUTRITIONAL STATUS
Gonzalez-Barba F1, Sat-Muñoz D2, Palomares-Chacon U3, Martinez-Herrera B4, Hernandez-Covarrubias O1, Balderas-Peña L1
1UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico, 2Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, 3UMAE HE Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social, Guadalajara, Mexico, 4Hospital General de Zona No. 2 "Dr. Francisco Padrón Puyou", San Luis Potosí, SLP, Mexico

PCN242
I8
HEALTH-RELATED QUALITY OF LIFE AFTER ONCOLOGICAL RESECTION AND RECONSTRUCTION OF THE CHEST WALL
Salo JT1, Repo JP1, Roine RP2, Sintonen H3, Tukiainen EJ1
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Helsinki University Hospital and University of Eastern Finland, Helsinki, Finland, 3University of Helsinki, Helsinki, Finland

PCN243
I9
ARE THERE DIFFERENCES IN FACT-G SCORES BETWEEN DIFFERENT TUMOUR TYPES FOR AN EU POPULATION USING REAL WORLD DATA?
Hallworth P1, Simpson S2, Bennett B2, Byrne K1, Rider A3, Desai T2, Cocks K4
1Adelphi Real World, Bollington, Cheshire, UK, 2Adelphi Values Ltd, Bollington, Cheshire, UK, 3Adelphi Real World, Cheshire, UK, 4Adelphi Values, Bollington, Cheshire, UK

PCN244
I10
APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY: LINKING SELF-REPORTED QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CANCER TO CLINICAL DATA FROM A GERMAN TUMOR REGISTRY
Borchert K1, Jacob C1, Wetzel N2, Jaenicke M2, Eggers E3, Sauer A4, Marschner N5, Meise D1, Altevers J1, Mittendorf T1, Braun S1, Greiner W6
1Xcenda GmbH, Hannover, Germany, 2iOMEDICO AG, Freiburg, Germany, 3Kreiskrankenhaus Torgau, Torgau, Germany, 4Medizinisches Versorgungszentrum für Blut- und Krebserkrankungen, Potsdam, Germany, 5Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Germany, 6University of Bielefeld, School of Public Health, Bielefeld, Germany

PCN245
I11
HEALTH-RELATED QUALITY OF LIFE IN ONCOLOGY – ARE WE GETTING BETTER?
Byrne K1, Simpson S2, Bennett B2, Rider A3, Hallworth P1, Desai T2, Cocks K4
1Adelphi Real World, Bollington, Cheshire, UK, 2Adelphi Values Ltd, Bollington, Cheshire, UK, 3Adelphi Real World, Cheshire, UK, 4Adelphi Values, Bollington, Cheshire, UK

PCN246
I12
IMPORTANT GROUP DIFFERENCES ON THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY–KIDNEY SYMPTOM INDEX DISEASE-RELATED SYMPTOMS (FKSI-DRS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Cella D1, Motzer R2, Rini BI3, Cappelleri JC4, Ramaswamy K5, Arondekar B6, Bushmakin AG7
1Northwestern University, Chicago, IL, USA, 2Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, USA, 3Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, 4Pfizer, Inc, Groton, CT, USA, 5Pfizer Inc., New York, NY, USA, 6Pfizer Inc, Collegeville, PA, USA, 7Pfizer Inc, Groton, CT, USA

PCN247
WITHDRAWN

CANCER - Health Care Use & Policy Studies
PCN248
I13
FEASIBILITY OF PRECISION ONCOLOGY VIRTUAL TUMOR BOARDS TO OPTIMIZE DIRECT POINT-OF-CARE MANAGEMENT AND CLINICAL TRIAL ENROLLMENT OF ADVANCED CANCER PATIENTS
Loaiza-Bonilla A1, Kurnaz S2, Johnston K2, Culcuoglu C2, Arango B2
1Cancer Treatment Centers of America, Philadelphia, PA, USA, 2Massive Bio, Inc, New York, NY, USA

PCN249
I14
SUBJECTIVE FINANCIAL BURDEN AMONG GERMAN CANCER PATIENTS - RELATIONSHIP OF THE PATIENTS’ ECONOMIC SITUATION AND SUBJECTIVE DISTRESS
Witte J1, Mehlis K2, Kudlich M2, Apostolidis L2, Walther J2, Greiner W1, Winkler E2
1Bielefeld University, School of Public Health, Bielefeld, Germany, 2University Hospital Heidelberg, Heidelberg, Germany

PCN250
I15
APPLYING NICE END OF LIFE CRITERIA IN THE ERA OF DRUG APPROVALS BASED ON SINGLE-ARM TRIAL DATA
Macaulay R1, Patel P2
1PAREXEL International, London, UK, 2PAREXEL International, Chandigarh, India

PCN251
I16
NICE AND SINGLE? RECOMMENDATION RATES OF ONCOLOGY THERAPIES APPROVED ON CLINICAL TRIAL PACKAGES LACKING COMPARATIVE PHASE 3 DATA
Macaulay R1, Anell B2
1PAREXEL International, London, UK, 2PAREXEL International, Stockholm, Sweden

PCN252
I17
INTERNATIONAL HTA EXPERIENCE WITH TARGETED THERAPY APPROVALS FOR LUNG CANCER
Maraiki F1, Byrnes J1, Tuffaha H1, Hider M2
1Griffith University, Brisbane, Australia, 2Hochschule Fresenius University of Applied Sciences, Idstein, Germany

PCN253
I18
ARE ACCELERATED APPROVAL MECHANISMS A PREDICTOR TO EARLY ACCESS AND COVERAGE? A GLOBAL STUDY OF CANCER DRUGS
Tzouma V, Efthymiadou O, Mills M, Kanavos P
London School of Economics and Political Science, London, UK

PCN254
I19
SURVIVAL EFFECT, DEMAND EFFECT AND POLICY EFFECT AS DRIVERS FOR PRICING OF INNOVATIVES ANTICANCER DRUGS
Aissaoui A1, Levy P2
1Paris Dauphine University, PSL, Paris, France, 2Université Paris-Dauphine, Paris, France

PCN255
I20
THE ROLE OF GENERAL PRACTITIONERS IN DIAGNOSTIC DELAY IN CASE OF CUTANEOUS MALIGNANT MELANOMA PATIENTS
Horváthné Kívés Z1, Boncz I1, Endrei D1, Sándor J2
1University of Pécs, Pécs, Hungary, 2University of Debrecen, Debrecen, Hungary

PCN256
I21
THE CLINICAL BURDEN OF HEAD AND NECK CANCER TO THE BRAZILIAN SOCIETY
Rosim MP1, Sarti FM1, Riveros B2, Lucchetta RC2, Pedro GO3, Scatena D3, Okumura LM4, Nita ME5, Massaoka MH6, Volsi EC6, Matsuo AL6, Guerra RL7, Santos M8, Stefani SD9
1University of Sao Paulo, sao paulo, Brazil, 2Federal University of Parana, Curitiba, Brazil, 3MAPES, São Paulo, Brazil, 4Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 5USP and FIPE/HAOC, Sao Paulo, Brazil, 6AstraZeneca, Cotia, Brazil, 7National Institute of Cancer, Rio de Janeiro, Brazil, 8Brasilia University, Brasilia, Brazil, 9Instituto do Câncer Mãe de Deus, Porto Alegre, Brazil

PCN257
I22
CLINICAL EFFICACY AND SAFETY OF LICENSED DRUGS AND POTENTIAL NEW THERAPIES FOR NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A SYSTEMATIC LITERATURE REVIEW
Naidoo S1, Smith I2, Casamayor M3
1Astellas Pharma, Inc, Chertsey, UK, 2Astellas Pharma, Inc., Chertsey, UK, 3QuintilesIMS, Barcelona, Spain

PCN258
I23
THE CLINICAL BURDEN OF BLADDER CANCER TO THE BRAZILIAN SOCIETY
Rosim MP1, Sarti FM1, Riveros B2, Lucchetta RC2, Pedro GO3, Scatena D3, Okumura LM4, Nita ME5, Massaoka MH6, Volsi EC6, Matsuo AL6, Guerra RL7, Fay AP8
1University of Sao Paulo, sao paulo, Brazil, 2Federal University of Parana, Curitiba, Brazil, 3MAPES, São Paulo, Brazil, 4Pontifícia Universidade Católica (PUC-RS), Porto Alegre, Brazil, 5USP and FIPE/HAOC, Sao Paulo, Brazil, 6AstraZeneca, Cotia, Brazil, 7National Institute of Cancer, Rio de Janeiro, Brazil, 8PUCRS - School of Medicine, Porto Alegre, Brazil

PCN259
I24
NAVIGATING THE ROAD TO REIMBURSEMENT AND OPTIMIZING UPTAKE FOR ONCOLOGY AGENTS IN THE EU5: PAYER AND PRESCRIBER PERSPECTIVES ON THE POWER OF PIVOTAL TRIAL DESIGN
Buckley N, Ammermann I, Vinuesa L, Cox J
Decision Resources Group, London, UK

PCN260
I25
INCIDENCE, MORTALITY AND TREATMENT OF MELANOMA IN POLAND IN THE YEARS 2012-2016
Polkowska M1, Staniak A2, Czepielewska E1, Wysoczański W3, Matusewicz W3, Kozłowska-Wojciechowska M1
1Medical University of Warsaw, Faculty of Pharmacy, Warsaw, Poland, 2Wroclaw Medical University, Wroclaw, Poland, 3Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, Poland

PCN261
I26
ROLE OF CHEMOTHERAPY IN THE CURRENT TREATMENT OF METASTATIC MELANOMA
Klink AJ1, Nabhan C2, Feinberg BA1
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN262
I27
OPIOID USE OUTCOMES AMONG FEMALE BREAST CANCER PATIENTS USING ADJUVANT ENDOCRINE THERAPY REGIMENS
Tan X1, Camacho F2, LeBaron V3, Blackhall L2, Balkrishnan R2
1West Virginia University, Morgantown, WV, USA, 2University of Virginia School of Medicine, Charlottesville, VA, USA, 3University of Virginia School of Nursing, Charlottesville, VA, USA

PCN263
I28
REAL-WORLD MANAGEMENT AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA IN ROMANIA AND POLAND
Dytfeld D1, Coriu D2, Fink L3, Hemetsberger M4, Bjorklof K5, Toka KS5, Gatta F5, Niepel D5
1University of Medical Sciences, Poznan, France, 2University of Medicine and Pharmacy “Carol Davila”, Bucharest, France, 3Kantar Health, Paris, France, 4Hemetsberger Medical Services, Vienna, Austria, 5Amgen (Europe) GmbH, Zug, Switzerland

PCN264
I29
THE GLOBAL BURDEN OF GASTRIC (GC) AND GASTROESOPHAGEAL JUNCTION (GEJC) CANCERS
Morlock R1, Duran A2, Holmstrom S3, Casamayor M4, Gani R5, Pandya BJ1, van Engen A6
1Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 2Astellas Pharma Europe Ltd., Chertsey, UK, 3Astellas Pharma Europe, B.V., Leiden, The Netherlands, 4QuintilesIMS, Barcelona, Spain, 5QuintilesIMS Consulting Services, Berkshire, UK, 6QuintilesIMS Consulting Services, Hoofddorp, The Netherlands

PCN265
I30
INITIATIVE TO OBTAIN ADVANCED THERAPEUTIC OUTCOMES IN MULTIPLE MYELOMA (IMPORTA PROJECT)
Blade J1, Calleja M2, Lahuerta J3, Poveda J4, de Paz H5, Lizan L5
1Hospital Clinic, Barcelona, Spain, 2Hospital Virgen Macarena, Sevilla, Spain, 3Hospital 12 de Octubre, Madrid, Spain, 4Hospital Universitario y Politécnico La Fe, Valencia, Spain, 5Outcomes 10, Universitat Jaume I, Castellon, Spain

PCN266
I31
THE FRENCH COMPASSIONATE USE OF MEDICINAL PRODUCTS PROGRAMME: A DRASTIC INCREASE OF EXPENDITURE OVER THE 2012-2016 PERIOD
Sam E, Coulonjou H, Mézerette B
French Ministry of Health, General Directorate for Healthcare Provision (DGOS/PF4), Paris, France

PCN267
I32
THE ARRIVAL OF THERAPEUTIC BIOSIMILARS IN ONCOLOGY: THE CASE OF TRASTUZUMAB
Barbier L1, Simoens S1, Declerck P1, Vulto A2, Huys I1
1KU Leuven, Leuven, Belgium, 2The Erasmus University Medical Center, Rotterdam, The Netherlands

PCN268
I33
TIME TO MARKET ACCESS FOR ONCOLOGY MEDICINES IN GREECE: HAS IT CHANGED DURING THE CRISIS?
Filosofou S1, Naoum P2, Kyriopoulos D2, Athanasakis K2, Theodorou M1
1Open University of Cyprus, Latsia, Nicosia, Cyprus, 2National School of Public Health, Athens, Greece

PCN269
WITHDRAWN

PCN270
I34
ONE YEAR REPORT CARD FOR THE CANCER DRUGS FUND REFORMS – FROM ABSURDITY TO IRRELEVANCE?
Walsh SC, Dave K, Tsang R, Macaulay R
PAREXEL International, London, UK

PCN271
I35
THE IMPACT OF CANCER DRUGS FUND REFORMS ON REIMBURSEMENT OF ONCOLOGY DRUGS IN THE UK
Macaulay R, Dave K, Walsh SC
PAREXEL International, London, UK

PCN272
J1
EXPERIENCES WITH PRICE COMPETITION OF BIOSIMILAR DRUGS IN HUNGARY
Hornyák L1, Nagy Z2, Tálos Z1, Endrei D2, Ágoston I2, Csákvári T3, Boncz I2
1Csolnoky Ferenc Hospital, Veszprém, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary

PCN273
J2
TREATMENT PATTERN OF PATIENTS DIAGNOSED WITH PROSTATE CANCER IN KOREA: A TREND ANALYSIS USING NATIONWIDE HEALTH INSURANCE DATABASE
Park E, Kang M, Shim J, Kang S, Yang J, Choi I
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea, Republic of (South)

PCN274
J3
PAYER MANAGEMENT OF HIGH-COST BRAND-ON-BRAND COMBINATION THERAPIES IN ONCOLOGY
Sherwin G, Gee A
ICON plc, LONDON, UK

PCN275
J4
CANCER DRUGS IN ALGERIA AND SIX OTHER COUNTRIES: A CROSS-COUNTRY PRICE COMPARISON STUDY.
Hedibel M, Kandi Z, Hidra RS
Faculty of Medecine Algiers, Algiers, Algeria

PCN276
J5
GERMAN AMNOG BENEFIT ASSESSMENT: THE TYPE OF APPROPRIATE COMPARATOR MAKES THE DIFFERENCE
Templin C, Billig S, Damen D, Kulp W
Xcenda GmbH, Hannover, Germany

PCN277
J6
RATES OF UPTAKE OF NOVEL AGENTS IN CANCER (PROSTATE, MELANOMA, AND LUNG): CONSIDERATIONS FOR FORECASTING IN ECONOMIC EVALUATIONS
Kish J, Feinberg B
Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN278
J7
CHARACTERISTICS OF PATIENTS TREATED WITH CETUXIMAB-BASED EXTREME REGIMEN IN 1ST LINE R/M SCCHN CANCER IN REAL LIFE SETTING, IN FRANCE IN 2012-2015.
Guigay J1, Chamorey E1, van Hille B2, Seronde A2, Le Tourneau C3
1Comprehensive Cancer Center Antoine Lacassagne, NICE Cedex 2, France, 2Merck s.a.s., LYON, France, 3Institut Curie, Paris, France

PCN279
J8
THE CASE FOR COMBINATION THERAPY - CLINICAL AND ECONOMIC VALUE DIFFERENTIATION STRATEGIES IN SATURATED ONCOLOGY THERAPY AREAS
Haycock L1, O'Rourke M1, Solon C2, Chalmers M1
1CBPartners, London, UK, 2CBPartners, San Francisco, CA, USA

PCN280
J9
ANALYSIS OF PHARMACY CLAIMS FOR HIGH COST DRUGS: RUXOLITINIB UTILISATION AND EXPENDITURE IN IRELAND
Hickey N1, Corcoran A1, Usher C2, Barry M1, McCullagh L1
1Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland

PCN281
J10
REAL-WORLD EVALUATION OF PHYSICIAN ATTITUDES TOWARDS THE PRESCRIPTION OF ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH PROSTATE CANCER
Wittrup-Jensen KU1, Hallworth P2, Alvarez ML3, Rider A4
1Ferring Pharmaceuticals, Copenhagen S, Denmark, 2Adelphi Real World, Bollington, Cheshire, UK, 3Ferring International Center SA, Saint-Prex, Switzerland, 4Adelphi Real World, Cheshire, UK

PCN282
J11
MANAGEMENT AND COST ANALYSIS OF CANCER PATIENTS TREATED WITH G-CSF: A COHORT STUDY BASED ON THE FRENCH NATIONAL HEALTHCARE INSURANCE DATABASE (ECHANTILLON GÉNÉRALISTE DES BÉNÉFICIAIRES)
Tilleul P1, Jacot W2, Emery C3, Lafuma A4, Gourmelen J5, Fabre N6, Gaudin H6
1Nantes Hospital University, nantes, France, 2Institut Régional du Cancer Montpellier, Montpellier, France, 3Cemka, Bourg La Reine, France, 4Cemka-Eval, Bourg La Reine, France, 5UMS 011 - Inserm - UVSQ, Villejuif, France, 6Chugai Pharma France, Puteaux, France

PCN283
J12
DEVELOPMENT AND EVALUATION OF ONCONURSE PRACTICE− A SMARTPHONE APPLICATION FOR ONCOLOGY NURSES
Chacko RJ1, Zaviour N2, Sekhar M S3
1MANIPAL UNIVERSITY, MANIPAL, India, 2MANIPAL UNIVERSITY, manipal, India, 3MCOPS, Manipal University, Manipal, India

PCN284
J13
PERSISTENCE, COMPLIANCE AND BISPHOSPHONATE SWITCHING IN PATIENTS WITH MULTIPLE MYELOMA (MM) IN GERMANY
Intorcia M1, Ansorge S2, Giannopoulou C1, Hohmann D3
1Amgen GmbH, Zug, Switzerland, 2arvato health analytics, Munich, Germany, 3Amgen GmbH, Munich, Germany

PCN285
J14
DENOSUMAB AND BISPHOSPHONATES PERSISTENCE, COMPLIANCE AND SWITCH IN PATIENTS WITH SOLID TUMORS (ST) AND BONE METASTASES (BM)
Diel I1, Ansorge S2, Hohmann D3, Giannopoulou C4, Intorcia M4
1Praxisklinik am Rosengarten, Mannheim, Germany, 2Gesundheitsforen Leipzig GmbH, Munich, Germany, 3Amgen GmbH, Munich, Germany, 4Amgen GmbH, Zug, Switzerland

PCN286
J15
WHAT IMPACT DOES NICE’S MODIFIED CANCER DRUGS FUND PROCESS MEAN FOR PATIENT ACCESS TO NEW ONCOLOGY PHARMACEUTICALS IN ENGLAND?
Craddy P1, Butler E2, Bailey S2, Wolfram V2, Foxon G2
1Remap Consulting, Zug, Switzerland, 2Remap Consulting, Cheshire, UK

PCN287
J16
CHANGES IN TREATMENT PATTERNS OF TYROSINE KINASE INHIBITORS AMONG NON-SMALL CELL LUNG CANCER PATIENTS UNDER THE NATIONAL HEALTH INSURANCE IN TAIWAN
Chang J1, Wang C2, Lin F1
1Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, 2School of Pharmacy, National Taiwan University, Taipei, Taiwan

PCN288
J17
NEW INSIGHTS IN METASTATIC COLORECTAL CANCER TREATMENT (MCRC) IN 5 EUROPEAN COUNTRIES
Kolb N, Reichert A, Menacher G, Mambrini T, von Bredow D
QuintilesIMS, Munich, Germany

PCN289
J18
PHYSIOTHERAPEAUTIC METHODS AIMED TO IMPROVE THE CARDIORESPIRATORY STATE BEFORE AND AFTER OPERATION IN PATIENTS WITH LUNG CANCER
Horváth K1, Bán B2, Szántó Z2, Ács P1, Boncz I1, Molics B1
1University of Pécs, Pécs, Hungary, 2Univesity of Pécs, Pécs, Hungary

PCN290
J19
ORPHAN DRUG REIMBURSEMENT IN EUROPE: DO LESS STRINGENT REGULATORY REQUIREMENTS TRANSLATE INTO LESS FAVOURABLE REIMBURSEMENT?
Anastasaki E, Macaulay R
PAREXEL International, London, UK

PCN291
J20
REGIONAL DIFFERENCES IN POTENTIAL SAVINGS FOR THE MEDICAL TREATMENT OF ADVANCED PROSTATE CANCER IN THE GERMAN HEALTH CARE SYSTEM
de Millas C, Höer A
IGES Institut GmbH, Berlin, Germany

PCN292
J21
SYSTEMATIC REVIEW OF PIVOTAL STUDIES OF ONCOLOGY DRUGS AUTHORIZED IN ITALY SINCE 2013: CORRELATION BETWEEN STUDIES’ MAIN CHARACTERISTICS AND TIME TO PATIENT
Prada M, Sansone C, Mantovani M
Intexo, Roma, Italy

PCN293
J22
HEALTH LOSS DUE TO MARKET ACCESS DELAYS AND REIMBURSEMENT RESTRICTIONS IN FIRST-LINE EGFR-POSITIVE NON-SMALL CELL LUNG CANCER IN THE EU5 COUNTRIES
van Nimwegen K1, Nientker K1, Boukouvalas S2
1Pharmerit International, Rotterdam, The Netherlands, 2Pharmerit International, York, UK

PCN294
J23
THE IMPRESS OF PHARMACOECONOMICS IN PRICING DECISIONS IN IFDA
Ghiasi G1, Nikfar S2
1Iran Food and Drug Organization, Tehran, Iran (Islamic Republic of), 2Tehran University of Medical Sciences, Faculty of Pharmacy, Tehran, Iran (Islamic Republic of)

PCN295
J24
AN EXPLORATORY COMPARISON OF US AND EU APPROACHES TO ONCOLOGY MANAGEMENT. ARE US PAYERS READY FOR MANAGEMENT TOOLS INCORPORATING HTA METHODOLOGIES?
Severi Bruni D1, Banks J2, Runyan A2
1MKO Global Partners, San Francisco, CA, USA, 2MKO Global Partners, San Diego, CA, USA

PCN296
J25
A COMPARATIVE ANALYSIS OF THE HEALTH CARE UTILIZATION AND COSTS OF PATIENTS DIAGNOSED WITH AND WITHOUT LIVER CANCER IN THE US MEDICARE POPULATION
Ogbomo A1, Lin Y1, Keshishian A1, Xie L1, Yuce H2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2New York City College of Technology-CUNY and STATinMED Research, New York, NY, USA, 3Columbia University/MEF University/STATinMED Research, New York, NY, USA

PCN297
J26
A RETROSPECTIVE DATABASE ANALYSIS OF TREATMENT PATHWAYS AND ESTIMATED COSTS OF TREATMENT IN METASTATIC COLORECTAL CARCINOMA (MCRC) IN GERMANY
Lebioda A1, Kolb N2, von Bredow D2, Kuhn A1
1Amgen GmbH, Munich, Germany, 2QuintilesIMS, Munich, Germany

PCN298
J27
DISEASE BURDEN DURING THE “WATCHFUL WAITING” PERIOD IN WOMEN WITH RECURRENT OVARIAN CANCER IN GERMANY
Harrow B1, Konieczny A2, Pignot M3, Wilk A4, Bala M1
1TESARO, Inc., Waltham, MA, USA, 2TESARO Inc., Waltham, MA, USA, 3Kantar Health, Munich, Germany, 4Team Gesundheit, Essen, Germany

PCN299
J28
COSTS AND LIFE EXPECTANCY INCREASED AMONG PATIENTS WITH BREAST CANCER ACROSS TWO TIME PERIODS
Lin Y1, Tang C1, Chien L1, Liao C2
1Taipei Medical University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan

PCN300
J29
GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF): POTENTIAL FINANCIAL SAVINGS FOR GERMAN HOSPITALS
Wahler S1, Müller A2
1St. Bernward GmbH, Hamburg, Germany, 2Analytic Services GmbH, München, Germany

PCN301
J30
SUBCUTANEOUS DRUGS IN ONCOLOGY: MAKE A DIFFERENCE IN THE TREATMENT? SYSTEMATIC REVIEW FROM DIFFERENT ANALYTICAL PERSPECTIVES
Medina Torres YA1, Gamboa Garay OA1, Moreno-Silva NA2, Díaz-Toro YR2
1Instituto para la Evaluación de la Calidad y Atención en Salud-IECAS, Bogotá, Colombia, 2Productos Roche S.A. Colombia, Bogotá, Colombia

PCN302
J31
DETERMINING THE COMPARATIVE VALUE OF OUTCOME-BASED MONEY-BACK GUARANTEE SCENARIOS IN NON-SMALL CELL LUNG CANCER USING REAL-WORLD DATA
Holleman MS1, van der Linden N2, Uyl-de Groot CA1
1Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Centre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney (UTS), Sydney, Australia

PCN303
J32
ECONOMIC ANALYSIS AND EVALUATION OF THE VALUE OF THE PARALLEL EXPORT OF MEDICINAL PRODUCTS FOR TREATMENT OF ONCOLOGICAL DISEASES IN BULGARIA, 2016 T. VEKOV 1 AND G. KOLEV2
Vekov T
Medical University Pleven, Pleven, Bulgaria

PCN304
J33
DO COUNTRIES WITH SIMILAR GDPS AND HEALTH EXPENDITURES REIMBURSE THE SAME CANCER DRUGS?
McKendrick J1, Malcolm B2, Sheahan K3, Katsoulis IA1, Song X1, van Loon J1
1PRMA Consutling, Fleet, UK, 2Bristol-Myers Squibb, Uxbridge, UK, 3Bristol Myers Squibb, Princeton, NJ, USA

PCN305
J34
ACCESS PERCEPTIONS: A KEY DRIVER OF NON-SMALL CELL LUNG CANCER (NSCLC) TARGETED THERAPY PRESCRIPTION IN RUSSIA
Graham A1, Byrne K2, Pepper K1, Silvey M1
1Adelphi Real World, Manchester, UK, 2Adelphi Real World, Bollington, Cheshire, UK

PCN306
J35
THE IMPACT OF THE STUDY DESIGN SUBMITTED FOR THE EARLY BENEFIT ASSESSMENT ON THE PRICING FOR ONCOLOGIC DRUGS
Beinhauer I1, Dintsios C2
1University of Cologne, Köln, Germany, 2Heinrich Heine University of Düsseldorf, Düsseldorf, Germany

PCN307
K1
THE DIFFERENCE BETWEEN REGULATORY AND MARKET ACCESS DECISIONS ON TREATMENT AVAILABILITY FOR NEW DRUGS IN SIX COMMON CANCERS ACROSS AUSTRALIA, CANADA, AND EUROPE
McKendrick J1, Malcolm B2, Sheahan K3, Katsoulis IA1, Song X1, van Loon J1
1PRMA Consutling, Fleet, UK, 2Bristol-Myers Squibb, Uxbridge, UK, 3Bristol Myers Squibb, Princeton, NJ, USA

PCN308
K2
SYSTEMATIC LITERATURE REVIEW ON MULTI-INDICATION PRICING MODELS IN ONCOLOGICAL DRUGS
Manganelli A1, Badia X2, Gonzalez P3
1CRES-UPF, Barcelona, Spain, 2Omakase Consulting, Barcelona, Spain, 3Bristol-Myers Squibb, Madrid, Spain

PCN309
K3
MANAGED ENTRY AGREEMENTS (MEA): ANALYSIS OF THE CURRENT SITUATION IN MIDDLE EAST AND NORTH AFRICA
Dokuyucu O1, Gol D1, Arslan B2, Incioglu F2, Ozbek O2
1AMGEN, Istanbul, Turkey, 2QuintilesIMS, Istanbul, Turkey

PCN310
K4
BARRIERS TO EFFECTIVE TREATMENT OF PATIENTS WITH CLL IN POLAND IN COMPARISON TO THE UNITED KINGDOM
Wladysiuk M, Rolska P, Stozek-Tutro A
HTA Consulting, Krakow, Poland

PCN311
WITHDRAWN

PCN312
K5
VARIATION IN HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT DECISIONS IN ENGLAND, FRANCE, AND GERMANY: SPOTLIGHT ON THE IMPACT OF UNCERTAINTY
Horscroft JA, Chapman A, Philips Z, Akehurst R
BresMed Health Solutions, Sheffield, UK

PCN313
K6
CHARACTERISTICS OF THE DIETARY HABITS OF CANCER PATIENTS AND STRUCTURE OF CONSUMPTION OF BASIC FOOD PRODUCTS
Batagoeva Z1, Sharmanov T2, Satbayeva E1, Seitaliyeva A1, Doszhanova B1, Esetova K1, Amirkulova M1, Parmankulova T1, Izatova A1, Kadyrova D1, Kim I1, Smagulova G1
1Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan, 2Kazakh Academy of nutrition, Almaty, Kazakhstan

PCN314
K7
BRCA1/2-MUTATED BREAST CANCER IN SELECT EU MARKETS: INCIDENCE, TREATABLE POPULATIONS, AND POTENTIAL MARKET SIZE FOR PARP INHIBITORS
Isherwood A1, Duval A1, Parihar N2
1Decision Resources Group, London, UK, 2Decision Resources Group, Bangalore, India

PCN315
K8
IMPACT OF TIME TO REIMBURSEMENT OF DRUG TREATMENTS FOR NON-SMALL CELL LUNG ON PATIENT OUTCOMES IN EUROPE AND LATIN AMERICA
Smith N, Meletiche D, Beckerman R
Maple Health Group, LLC, New York, NY, USA

PCN316
K9
EMERGING MARKETS TIERED PRICING: A QUANTITATIVE ASSESSMENT OF LOCAL AFFORDABILITY AND EXISTING PRICE TO PATIENT
Walsh K, Jaffar S, Thakerar S
Navigant Consulting, London, UK

PCN317
K10
ACUTE LYMPHOBLASTIC LEUKAEMIA’S BURDEN OF DISEASE IN PORTUGAL
Paquete AT, Alarcão J, Fiorentino F, Guerreiro R, Silva Miguel L, Borges M
Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

PCN318
K11
REVIEW OF REAL-WORLD EVIDENCE TO ASSESS THE BURDEN OF ILLNESS OF MANTLE CELL LYMPHOMA
Monga N1, Garside J2, Quigley JM3, O'Rourke JM3, O'Donovan P3, Padhiar A3, Parisi L4, Tapprich C5
1Janssen Global Oncology, Toronto, ON, Canada, 2Janssen, High Wycombe, UK, 3ICON Health Economics & Epidemiology, Abingdon, UK, 4Janssen Global Oncology, Raritan, NJ, USA, 5Janssen Pharmaceuticals, Neuss, Germany

PCN319
K12
ASSESSING THE IMPLICATIONS OF THE NICE BUDGET IMPACT TEST: HOW MANY ONCOLOGY REGIMENS WILL BE AFFECTED AND WHAT WILL BE THE IMPACT ON PATIENT OUTCOMES?
Tuson HA, Dunsch AK, Song X
PRMA Consulting, Fleet, UK

PCN320
K13
RELEVANCE OF REAL WORLD DATA IN GERMAN AMNOG SUBMISSIONS IN ONCOLOGY
Haas JS, Borchert K, Loepmeier J, Braun S, Mittendorf T
Xcenda GmbH, Hannover, Germany

PCN321
K14
A REVIEW OF THE APPROACHES USED TO MODEL SUBSEQUENT TREATMENTS IN NICE ECONOMIC EVALUATIONS: EXAMPLES WITHIN MULTIPLE MYELOMA AND RENAL CELL CARCINOMA
Lee D1, Gudala K2, Morgan P1
1BresMed Health Solutions Ltd., Sheffield, UK, 2BresMed Health Solutions Ltd., Gurugram, India

PCN322
K15
REVIEW OF PUBLISHED HEALTH-ECONOMIC APPRAISALS BY THE HAUTE AUTORITE DE SANTE (HAS) IN ADVANCED MELANOMA
Petitjean A, Cartier-Bechu C, Gouzy C, Roze S
HEVA HEOR Sarl, Lyon, France

PCN323
K16
VALUE FRAMEWORKS FOR CANCER CARE: DO THEY ACCOUNT FOR POTENTIAL DURABLE SURVIVAL WITH IMMUNOTHERAPY?
Ben-Aharon O1, Magnezi R1, Leshno M2, Goldstein DA3
1Bar-Ilan University, Ramat-Gan, Israel, 2Tel-Aviv University, Tel Aviv, Israel, 3Rabin Medical Center, Petach-Tikva, Israel

PCN324
K17
A COMPARISON OF THE APPRAISALS BY THE ENGLISH NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) FOR TWO THERAPIES FOR RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): IDELALISIB+RITUXIMAB (IR) AND IBRUTINIB
Thompson G, Hassan F, Lee J
Janssen UK, High Wycombe, UK

PCN325
K18
TRENDS IN ONCOLOGY APPRAISAL DECISIONS: A COMPARISON BETWEEN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE SCOTTISH MEDICINES CONSORTIUM (SMC)
Campbell DJ1, Clark RS2, Meyer KL2
1Xcenda, Palm Harbor, FL, USA, 2Xcenda, LLC, Palm Harbor, FL, USA

PCN326
K19
MARKET ACCESS CHALLENGES TO PD-1 IMMUNOTHERAPIES: LESSONS FROM NICE
McLean T, Tavella F, Heron L
Adelphi Values Ltd, Bollington, UK

PCN327
K20
PROS IN ONCOLOGY HTA DECISIONS, DO THEY MATTER?
Hintzen CL1, Lie X2, van Engen A2, New MJ3
1Utrecht University, Utrecht, The Netherlands, 2QuintilesIMS, Hoofddorp, The Netherlands, 3QuintilesIMS, Reading, UK

PCN328
K21
KEY DRIVERS IN HEALTH TECHNOLOGY ASSESSMENT BY ANALYSING THE LEVEL OF IMPROVEMENT IN ACTUAL BENEFIT IN SOLID TUMOR ONCOLOGY DRUGS
Bouschon M1, Li J2, Barthelemy C3
1Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, 2Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, 3Assisance Publique des Hôpitaux de Paris (AP-HP), Paris, France

PCN329
K22
THE ROLE OF COMPANION DIAGNOSTICS IN HTAS OF DRUGS IN FRANCE, GERMANY AND THE UK
Jones C, Lazos O, Gijsen M
PRMA Consulting, Fleet, UK

PCN330
K23
THE UNIQUE CHARACTERISITCS OF ADOPTIVE IMMUNOTHERAPIES FOR HEALTH ECONOMIC EVALUATIONS
Green W
York Health Economics Consortium, York, UK

PCN331
K24
ASSESSMENT OF HEALTH TECHNOLOGY APPRAISALS TO IDENTIFY KEY DRIVERS FOR REIMBURSEMENT OF ONCOLOGY DRUGS WITH ONLY PHASE 2 CLINICAL DATA
Duran A1, Morlock R2, Lie X3, Dekkers R3, Gani R4, van Engen A3, Holmstrom S5
1Astellas Pharma Europe Ltd., Chertsey, UK, 2Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 3QuintilesIMS Consulting Services, Hoofddorp, The Netherlands, 4QuintilesIMS Consulting Services, Berkshire, UK, 5Astellas Pharma Europe, B.V., Leiden, The Netherlands

PCN332
K25
ADC, NOT AS EASY AS 123 - THE UNPRECEDENTED EXAMPLE OF TRASTUZUMAB-EMTANSINE IN THE NICE APPRAISAL PROCESS
Wang GD, Macaulay R
PAREXEL International, London, UK

PCN333
K26
GUIDELINE ADHERENCE IN DOCETAXEL TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER (CRPC) PATIENTS IN A REAL-WORLD POPULATION: THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (CAPRI) IN THE NETHERLANDS
Westgeest H1, Kuppen M1, Van den Eertwegh A2, Gerritsen W3, Uyl - de Groot C1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands, 3Radboud University Medical Center, Nijmegen, The Netherlands

PCN334
K27
REAL-WORLD UTILIZATION OF BLINATUMOMAB IN ACUTE LYMPHOBLASTIC LEUKEMIA IN THE US
Radtchenko J1, Smith Y2, Feinberg B2
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN335
K28
REAL-WORLD MULTIPLE MYELOMA TREATMENT PATTERN IN LEBANON: EVIDENCE FROM PATIENT CHART AUDIT
Dokuyucu O1, Gol D1, Gatta F2, Molinier S3, Ibrahim A4
1AMGEN, Istanbul, Turkey, 2AMGEN, Zug, Switzerland, 3A Plus A Research, Lyon, France, 4Makassed University Hospital & Middle East University Hospital & Lebanese University Lebanon, Beirut, Lebanon

PCN336
K29
REAL-WORLD MULTIPLE MYELOMA TREATMENT PATTERN IN MOROCCO: EVIDENCE FROM PATIENT CHART AUDIT
Dokuyucu O1, Gol D1, Gatta F2, Molinier S3, Sedrati M4, Serraj K5
1AMGEN, Istanbul, Turkey, 2Amgen (Europe) GmbH, Zug, Switzerland, 3A Plus A Research, Lyon, France, 4Amgen Morocco, Casablanca, Morocco, 5University hospital mohammed VI, Oujda, Morocco

PCN337
K30
THE IMPLEMENTATION OF ROBOTIC-ASSISTED SURGERY FOR ENDOMETRIAL CANCER IN THE UNITED STATES LEAD TO AN IMPROVEMENT OF OVERALL 30-DAY SURGICAL OUTCOMES WITHOUT INCREASING COSTS: IS TECHNOLOGY FINALLY ALLOWING THE DIFFUSION OF MINIMALLY INVASIVE SURGERY AT A NATIONAL LEVEL?
Casarin J1, Song C2, Multinu F1, Liu E2, Butler K1, Glaser G1, Ghezzi F3, Mariani A1
1Mayo Clinic, Rochester, MN, USA, 2Intuitive Surgical, Sunnyvale, CA, USA, 3Università degli Studi, Varese, Italy

PCN338
K31
TRUCS AND CAR-TS - THE EMERGENCE OF IO CELL THERAPIES
Wang GD, Macaulay R
PAREXEL International, London, UK

PCN339
K32
IMPACT OF USING OVERALL SURVIVAL OR PROGRESSION-FREE SURVIVAL IN OUTCOMES-BASED PRICING ARRANGEMENTS
Florschütz KS, Rutten-van Mölken MP
Erasmus University Rotterdam, Rotterdam, The Netherlands

PCN340
K33
REAL-WORLD PATIENT CHARACTERISTICS AND PATTERNS OF CARE AMONG METASTATIC UROTHELIAL, HEAD AND NECK, NON-SMALL CELL LUNG CANCER PATIENTS USING A GERMAN SICKNESS FUND CLAIMS DATABASE
Klein AB1, Shire N1, Winget M2, Wang H1, Wilk A3, Pignot M4
1AstraZeneca, Gaithersburg, MD, USA, 2Kantar Health, St. Louis, MO, USA, 3Team Gesundheit, Essen, Germany, 4Kantar Health, Munich, Germany

PCN341
K34
REAL WORLD TREATMENT PATTERNS OF PATIENTS WITH OVARIAN CANCER RECEIVING FIRST LINE CHEMOTHERAPY IN THE UNITED STATES
Yu N1, Xiao Y2, Yi J3, Oliveri D3, Houghton R4, Luhn P2
1Roche, Welwyn Garden City, UK, 2Genetech, South San Francisco, CA, USA, 3Genesis Research, Hoboken, NJ, USA, 4Roche, Basel, Switzerland

PCN342
K35
TREATMENT PATTERNS OF SECOND-LINE (2L) METASTATIC UROTHELIAL CANCER (MUC) IN SPAIN
Clark OA1, Jaffe D2, DeCongelio M3, Li VW3, Goulden S4, Gonzalez P5, Gooden KM6
1Evidencias - Kantar Health, Campinas, NJ, Brazil, 2Kantar Health, Tel Aviv, Israel, 3Kantar Health, New York, NJ, USA, 4Bristol-Myers Squibb, Uxbridge, UK, 5Bristol-Myers Squibb, Madrid, Spain, 6Bristol-Myers Squibb, Lawrenceville, NJ, USA

PCN343
L1
REAL WORLD TREATMENT PATTERNS AND RESOURCE USE FOR ADVANCED NON-SMALL CELL LUNG CANCER IN BRAZILIAN PRIVATE INSTITUTIONS
Baldotto CS1, Mascarenhas ES2, Laloni MT3, Wiermann EG4, Kussumoto C5, Azevedo CR6, Julian GS7, Moreira Ed7, Aratangy G8, Tanaka S8, Bernardino G8
1Instituto COI de Educação e Pesquisa, CA, Rio de Janeiro, RJ, Brazil, Rio de Janeiro, Brazil, 2Núcleo de Oncologia da Bahia, Salvador, BA, Brazil, Salvador, Brazil, 3Centro Paulista de Oncologia, São Paulo, SP, Brazil, São Paulo, Brazil, 4IInstituto de Oncologia do Paraná, Curitiba, PR, Brazil, Curitiba, Brazil, 5Centro de Oncologia e Hematologia, Joinville, SC, Brazil, Joinville, Brazil, 6Multihemo Oncologia e Hematologia, Recife, PE, Brazil, Recife, Brazil, 7Evidências - Kantar Health, São Paulo, Brazil, 8Bristol-Myers Squibb, São Paulo, Brazil

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.